Gastroesophageal reflux disease

Gastroesophageal reflux disease (GERD) is a chronic condition in which gastric contents, mainly acid and pepsin but sometimes bile, move back into the esophagus and cause either troublesome symptoms or injury to the esophageal lining. Its most common expression is heartburn and regurgitation, but its spectrum runs from symptom-only disease without visible damage to erosive esophagitis, stricture, and Barrett esophagus. The modern clinical definition, set out in the Montreal Consensus, rests on symptoms, and it was later refined by the Lyon Consensus, which requires objective evidence before the diagnosis is conclusive. The condition sits at the boundary of gastroenterology, pharmacology and surgery, and the mechanisms are closely tied to the stomach and to the acidity of its contents.

GERD is one of the most common disorders treated in gastroenterology. Estimates of its prevalence vary widely by region and by diagnostic method, but it affects a substantial share of adults in many countries, and its burden has been rising in parts of Asia alongside changes in diet, body weight and lifestyle. Because the disease is long-lasting and often requires long-term medication, it has significant consequences for public-health, health-system costs and quality of life. Its extraesophageal effects, such as chronic cough, laryngeal irritation and asthma-like symptoms, also make it relevant to respiratory medicine and otolaryngology-placeholder.

This article describes GERD from its anatomical and physiological basis through its clinical presentation, classification, diagnosis and management. It covers the evolution of diagnostic criteria, the role of ambulatory monitoring and endoscopy, the principles and limits of medical, lifestyle and surgical therapies, and the unresolved questions that remain active research topics.

Definition and terminology

In physiology, reflux is the passive retrograde movement of gastric contents into the esophagus. It needs no active propulsion: when intra-abdominal pressure exceeds the pressure at the gastro-oesophageal junction, or when that barrier relaxes, stomach contents move upward. Gastric contents include hydrochloric acid, pepsin and, in some cases, duodenal bile, so the refluxate is chemically active in the esophagus. Brief episodes of reflux occur in healthy adults, especially after meals, and are normally cleared by swallowing and peristalsis without producing symptoms or damage. This is usually called physiological reflux. Reflux becomes pathological when its frequency, duration or volume exceeds the esophagus's capacity to clear it, or when the episodes cause symptoms or injury to the mucosa. The boundary between the two is a matter of degree and depends on the measurement used, which is why objective testing and symptom assessment are often reported separately.

The most widely cited definition of gastro-oesophageal reflux disease (GERD) comes from the Montreal Consensus, an international expert statement published in 2006. It describes GERD as a condition that develops when the reflux of stomach contents causes troublesome symptoms and/or complications. The definition is deliberately broad and does not require endoscopic evidence of injury. It made symptom burden and clinical consequences the defining feature of the disease, and it gave clinicians a practical framework that could be applied in primary care without specialist equipment. Its later revisions and the Lyon Consensus discussed in other sections extended this framework to objective measurements.

The name of the condition varies by region and context. "GERD" is the standard abbreviation in North American publications and in most guidelines written in American English. "Gastro-oesophageal reflux disease", with British spelling, is common in the United Kingdom, Europe and Commonwealth countries, and the two terms refer to the same condition. "Acid reflux" and "heartburn" are lay terms; heartburn is also a specific symptom that may or may not indicate GERD. Older literature used the term "reflux oesophagitis" (or "reflux esophagitis"), which put the mucosal lesion at the center of the concept. Its replacement by the broader term reflects the recognition that many patients with reflux symptoms have no visible inflammation at endoscopy, and that a disease defined only by erosive injury would miss a large part of the affected population.

The term is used differently in clinical practice and in research. In routine care, GERD is usually a working diagnosis based on typical symptoms and, often, a response to acid-suppressive treatment. In research, investigators must choose operational definitions, and these may require erosive esophagitis, abnormal acid exposure on pH monitoring, or symptoms with a documented temporal link to reflux. Studies using different definitions report very different prevalence and treatment outcomes, so the same label can describe quite different patient populations. The distinction between symptom-only and mucosal-injury definitions remains one of the central methodological issues in the field, and it underlies the classification debates covered in later sections.

Epidemiology and risk factors

Prevalence and why estimates diverge

A 2020 systematic review and meta-analysis put the pooled global prevalence at 13.98%, but the figure varied widely by region, from 12.88% in Latin America and the Caribbean to 19.55% in North America, and by country, from 4.16% in China to 22.40% in Turkey. Applying United Nations population data to that rate implied roughly 1.03 billion individuals affected worldwide. An earlier pooled analysis of symptom-based reflux, using a definition of at least weekly heartburn or regurgitation, reported 13.3% (95% CI: 12.0–14.6%).

The main reason figures differ is the definition. Estimates depend on symptom frequency thresholds, the questionnaire used, and whether a physician diagnosis counts. One review found that the pooled prevalence ranged from 5.17% in studies using the Reflux Disease Questionnaire to 26.90% in studies using other instruments. Study design, sampling, ethnic and genetic background, and lifestyle also contribute, as reviewers have noted, such marked variation may reflect differences in diagnostic criteria, symptom definitions, study design, sampling strategies, genetic or ethnic susceptibility, and lifestyle patterns. Criteria matter even within a single setting: applying the Lyon Consensus 2.0 criteria, conclusive GERD was diagnosed in 13.0% of Asian patients compared to 23.7% of US patients. Prevalence is also higher in specific groups. In a pooled analysis of pregnant women, the pooled prevalence of GERD symptoms during pregnancy was 40.96%, and the burden was greatest especially in the third trimester.

Regional and temporal trends

Reflux was long regarded as uncommon in East Asia. A systematic review of Asian studies found that symptom-based GERD in Eastern Asia ranged from 2.5%–4.8% before 2005 and 5.2%–8.5% from 2005 to 2010, while in Southeast and Western Asia, it was 6.3%–18.3% after 2005. Endoscopic data show a similar direction: the prevalence of endoscopic reflux esophagitis in Eastern Asia increased from 3.4%–5.0% before 2000 to 4.3%–15.7% after 2005.

Longitudinal evidence is more limited. A Singapore follow-up reported a rise in reflux symptoms from about 1.6% to nearly 10% over five years, but only a small percentage of the initial cohort of patients participated in the follow-up study, and response bias may have contributed to this apparent increase in prevalence. Explanations for the rise have centred on changes in diet and body weight. Researchers in China have tied the increase to shifting lifestyle and eating patterns, and a comparable pattern in the Middle East has been attributed to rising obesity levels, sedentary lifestyles, and increased consumption of fast food and caffeinated beverages. The contribution of Western diets remains unverified; one review stated that further research is required to verify the effect of a Western diet and way of life on GERD prevalence. Burden estimates for China also show growth in absolute numbers: between 1990 and 2021, the prevalence rate rose by 50.36%, although part of the change in case counts reflects population growth and ageing.

Established risk factors

Obesity and hiatal hernia are the anatomical factors most consistently linked to reflux. Reviews describe anatomical factors, such as hiatal hernia and obesity, which act alongside motor abnormalities such as weak lower esophageal sphincter tone. Pregnancy raises risk through hormonal and mechanical changes, as described above. Among modifiable exposures, a Saudi meta-analysis listed smoking, NSAID use, fast food, spicy food, and tea/coffee consumption as associated factors. Alcohol, high-fat meals, large meals, and eating close to bedtime are also commonly cited, though their effects vary between individuals. Certain medications, including some drugs that lower sphincter tone or irritate the mucosa, are discussed further in the pharmacology and special-population sections.

Sex, age and familial aggregation

Reported sex differences are inconsistent. One analysis found reflux affects 8–33% of the population without differences among sex, and it can be observed among all age groups, and a Saudi study reported similar rates in both genders. Other studies have identified sex as a significant factor. In an Iranian cohort, gender, region of residence, educational level, and depression symptoms were among the main risk factors. In a Japanese population, the factors associated with reflux esophagitis included old age, male, moderate working burden, divorced/widowed and strong tea drinking, which suggests that age and sex effects may depend on the outcome studied.

Family history is a recognised risk marker. First degree relatives of patients with GORD are more likely to suffer with GORD symptoms. Twin studies provide quantitative estimates. In a Swedish twin cohort, heritability accounted for 31% (23%-39%) of the liability to reflux disease. A UK twin study found casewise concordance rates were significantly higher for MZ than DZ twins (42% v 26%; p<0.001), with a heritability estimate of 43%. Genome-wide studies explain far less: one analysis estimated an SNP heritability of 7% (95% CI 3–11%) for GERD, which suggests that common variants individually contribute small effects and that much of the familial risk remains unexplained.

Anatomy and physiology of the gastroesophageal barrier

Anti-reflux structures

The gastroesophageal junction keeps gastric contents in the stomach through several structures that work together. The lower esophageal sphincter (LES) is the intrinsic component: a zone of smooth muscle, roughly the distal 3–4 cm of the esophagus, that stays under tonic contraction at rest. Its lower segment lies in the abdominal cavity, and the sling and clasp fibres of the gastric cardia are thought to act as a flap valve at this point. The crural diaphragm is the extrinsic component. It is skeletal muscle that wraps around the esophageal hiatus, contracts during inspiration and abdominal straining, and pinches the proximal LES. The right crus is also attached to the LES through the phrenoesophageal ligament, which provides additional support. The angle of His, the acute angle between the distal esophagus and the cardia, works as a flap, and its sharpness affects how easily material passes in either direction. Current descriptions stress that these elements are interdependent rather than independent. The LES preserves closure and the angle of His even when the crura relax, while the crura reinforce closure when intra-abdominal pressure rises.

Transient LES relaxation

Most reflux episodes in healthy people and in most patients with GERD occur through transient lower esophageal sphincter relaxations (TLESRs). These are LES relaxations that occur without a swallow, last longer than swallow-induced relaxations, and are accompanied by inhibition of the crural diaphragm and usually by the absence of peristalsis. Estimates of their share of reflux episodes vary between studies, from roughly half to nearly 90 percent, depending on the population and the measurement method. Gastric distension, particularly of the fundus after large or fat-rich meals, increases their frequency. Distension is thought to activate gastric stretch receptors and a vagal reflex, although the question of whether a purely mechanical opening of the cardia contributes has been examined with combined manometry and videoendoscopy. Those studies found that LES relaxation consistently precedes opening of the gastroesophageal junction, which supports a neurally mediated mechanism. Reflux through the junction requires a positive pressure gradient from stomach to esophagus during these events, and the process is facilitated by a shortened esophagus and inhibited crural contraction. TLESRs also have a physiological role, since they allow gas to vent from the stomach, which is why antireflux surgery tends to reduce the ability to belch. Hiatal hernia is associated with longer TLESR episodes, especially at night. In a less common pattern, a basal LES pressure that is persistently low allows reflux that is continuous rather than episodic.

Esophageal clearance

Once refluxate enters the esophagus, clearance proceeds in two phases. Volume clearance relies on gravity and peristalsis: primary peristalsis after a swallow removes most of the refluxed bolus, and secondary peristalsis, triggered by stretch receptors in the esophageal wall, removes most of the remaining volume. Chemical clearance then neutralizes the residual acid film. The main buffer is bicarbonate in saliva, both swallowed saliva and secretions from submucosal glands. A post-reflux swallow-induced peristaltic wave, elicited by an esophago-salivary vagal reflex, carries salivary bicarbonate and epidermal growth factor into the distal esophagus, raising luminal pH and supporting repair. Saliva flow usually rises with the onset of heartburn, and excess salivation with heartburn, known as waterbrash, may represent a protective response. Clearance is much less effective during sleep, when swallowing is infrequent and saliva production is low. Reduced saliva production, as in Sjögren syndrome, and esophageal hypomotility both impair pH recovery after reflux.

Mucosal defense of the esophagus

Protection is organized in layers. The antireflux barrier limits the frequency and volume of reflux, clearance limits how long gastric contents stay in contact with the epithelium, and tissue resistance protects the epithelium when contact is prolonged. The esophageal lining is a non-keratinized stratified squamous epithelium. Unlike the stomach, it has no continuous surface layer of mucus and bicarbonate, so its resistance depends on the epithelial cells themselves, including intercellular junctions that limit back-diffusion of hydrogen ions, intracellular buffering, and the capacity for repair. The gastric mucosa is a simple columnar epithelium covered by a mucus-bicarbonate gel, and it renews its surface cells within days. Its acid is generated and contained within a specialized environment. The duodenum, which is also exposed to acid, is protected by bicarbonate-rich secretions from pancreatic and Brunner gland sources that neutralize the chyme entering it. The esophagus thus depends mainly on external clearance rather than on a secretory buffer layer, which helps explain why prolonged acid contact damages it more readily than the gastric or duodenal mucosa.

Pathophysiology and mechanisms of injury

Chemical injury of the esophageal epithelium

Mucosal damage in reflux disease is usually explained by several noxious components of refluxate acting together. Beyond acid, pepsin, bile acids (salts), alkaline substances and food particles have been identified as additional contributors to histological damage, and exposure to this mixture causes direct epithelial injury and acute inflammation. The combination of pepsin and acid is thought to be more aggressive than acid alone.

Acid is generally regarded as the main initiating agent. In squamous epithelium, the earliest change is thought to be intercellular edema, seen as dilated intercellular spaces, together with faster loss of surface keratinocytes. The proliferative zone responds by increasing cell number and activity, which thickens the basal cell zone; this thickening can be seen morphologically when it exceeds 30% of epithelial thickness.

Pepsin, a gastric proteolytic enzyme, contributes by degrading extracellular proteins and disrupting cellular defenses. Its activity is highest at low pH: maximal enzymatic activity of pepsin occurs at pH levels below 3. Pepsin can also be reactivated during a new reflux episode once pH falls below 6.0, so injury may recur even when acid levels are modest. Pepsin has been found at high concentrations in patients with stricture or Barrett esophagus, which suggests it accumulates in chronically injured tissue.

Bile salts and loss of barrier integrity

Bile salts, particularly in acidic form, weaken the squamous barrier. Experimental work on human esophageal epithelial cells shows that acidified bile salts alter tight junction proteins. Pepsin and gastric acid are thought to degrade tight junction components such as claudin-1, claudin-2, claudin-4, ZO-1 and occludin, which is considered another significant pathological step in GERD. Researchers have also shown that acute exposure to acid and pepsin can widen epithelial tight junctions and increase permeability.

In GERD mucosa, the barrier is less effective. Histologically, impaired barrier integrity appears as dilated intercellular spaces, and functionally it shows increased permeability, reflected by reduced mucosal impedance and greater paracellular flux of molecules. Noxious luminal agents can then penetrate into the deeper basal layers and the underlying subepithelial tissue.

Inflammatory and cytokine-mediated injury

Histopathological and animal studies have led many investigators to view esophageal damage as more than a direct chemical effect. Damage is thought to be inflicted by inflammatory cells that infiltrate the mucosa in response to cytokines released by squamous epithelial cells exposed to acid and bile. Exposure of the epithelium to acid, bile salts and pepsin stimulates the release of proinflammatory cytokines including interleukin-1, -6, -8, -10 and tumor necrosis factor-α, which promotes the proliferation of T cells and neutrophils, contributing to chronic inflammation and oxidative stress. Subepithelial cells also participate: human esophageal myofibroblasts exposed to reflux-like conditions release factors that increase proliferation in the squamous epithelium. Cytokine levels such as IL-6, IL-8 and NF-κB have been reported to fall after proton pump inhibitor therapy, which links acid suppression to a reduction in this inflammatory signal.

Mechanical promotion of reflux

Acid and bile are only harmful if they reach the esophagus, so mechanical factors matter. Weak lower esophageal sphincter pressure allows the gastroesophageal junction to open more easily. A hiatal hernia displaces the junction above the diaphragm, reduces the support of the crural muscles and weakens the anti-reflux barrier. Raised intra-abdominal pressure, as occurs with obesity, pregnancy, straining or tight clothing, pushes gastric contents toward the esophagus. These mechanisms are described in more detail in the anatomy and physiology section.

Visceral hypersensitivity and central modulation

Symptom generation is not explained by mucosal damage alone. Visceral hypersensitivity refers to viscera reacting strongly to nociceptive stimuli, or reacting abnormally to physiological stimuli, because the visceral pain threshold has fallen. In visceral hypersensitivity, the mechanisms proposed include abnormal neurotransmitters, activation of acid-sensitive receptors, and abnormal psychological factors. Serotonin acting on 5-HT3 receptors has been proposed to modulate the esophageal response to distension and visceral perception. The central nervous system further shapes how the sensory signal is perceived, and anxiety and depression are commonly found alongside reflux symptoms. This is most evident in non-erosive disease: in prolonged pH studies, 30–50% of NERD patients had normal acid exposure times but experienced reflux hypersensitivity.

Debated contributors

Several other mechanisms remain uncertain. Post-gastrectomy patients have reflux that contains acid, bile and pancreatic enzymes, and mixed reflux is associated with mucosal injury and with symptom variation depending on whether acid is present. Whether duodenogastric reflux contributes in patients with intact anatomy is less clear. Non-acid reflux has also been implicated: one review notes that non-acid reflux contributes to neurogenic airway inflammation and heightened cough reflex sensitivity.

The esophageal microbiome is a further candidate. Microbial profiles differ between non-erosive disease, erosive disease, Barrett esophagus and adenocarcinoma, but the role of microbiota in gut–brain crosstalk is still far from established. Authors have suggested, without proof, that sulfate-reducing Proteobacteria and Bacteroidetes, together with hydrogen-producing Dorea, may play a mechanistic role in visceral hypersensitivity. Whether these changes are causes, consequences or bystanders of disease remains open.

Clinical manifestations: typical and atypical symptoms

Typical symptoms

The cardinal symptoms of GERD are heartburn and regurgitation. In the Montreal framework, heartburn is a burning sensation behind the sternum, and regurgitation is the perception that refluxed gastric contents are moving into the mouth or hypopharynx. The consensus regarded these two symptoms as descriptive enough to support a diagnosis on their own. Patients commonly describe a burning sensation that rises toward the chest and may spread to the neck, throat, or, less often, the back. In research, the two symptoms are frequently reported together as "heartburn or regurgitation," which makes it difficult to compare studies that measure them separately.

In the clinical history, the clinician establishes how often symptoms occur, how severe they are, and how much they interfere with daily life. The last point matters because occasional heartburn is common in the general population and does not by itself constitute disease. Practical history questions usually concern timing relative to large or high-fat meals, whether bending forward or lying down worsens symptoms, and whether antacids provide prompt relief. Secondary complaints such as sleep disturbance, water brash (regurgitation of saliva), nausea, and belching are also recorded, since they help place the presentation within the wider GERD spectrum.

Atypical and extraesophageal symptoms

The Montreal consensus grouped chest pain, sleep disturbance, cough, hoarseness, asthma, and dental erosion with the esophageal syndromes as extraesophageal manifestations. Proposed mechanisms include direct injury to the laryngeal and pharyngeal mucosa by refluxed material, microaspiration into the airways, and reflex stimulation through vagal afferent fibres in the esophagus. Laryngeal manifestations include hoarseness, throat clearing, and laryngitis, while globus sensation (a feeling of a lump in the throat) is frequently listed among atypical complaints.

Chest pain is the most consequential of these symptoms because it overlaps with cardiac disease. Noncardiac chest pain may arise from esophageal nociceptors, spasm, or hypersensitivity. A systematic review found that a PPI trial relieved noncardiac chest pain mainly in patients with erosive esophagitis or abnormal acid exposure, and not in those whose endoscopy and pH monitoring were normal. Chronic cough has a similar pattern. Open-label studies reported improvement in a substantial share of patients after empirical PPI treatment, but placebo-controlled trials and a meta-analysis did not provide sufficient support for a benefit. Subsequent data suggest that the response is more likely in patients who also have objective evidence of reflux. Asthma has been proposed as a reflux-associated condition, but evidence is limited, and the pediatric data are considered the more supportive.

Attributing atypical symptoms to reflux

The attribution of atypical symptoms to reflux remains contested. Most of these symptoms are nonspecific and occur in many conditions besides GERD, and the statistical association with reflux is modest; reported odds ratios range from about 1.2 to 3, with nocturnal cough showing the strongest link. Clinicians therefore generally exclude cardiac, pulmonary, and laryngeal causes before assigning symptoms to reflux. Guidelines recommend objective testing for chest pain only after adequate cardiac evaluation, and some clinicians use a PPI challenge to decide whether reflux is likely. Critics note that empirical PPI prescribing in otolaryngology clinics often rests on laryngoscopy findings and symptoms alone, and that endoscopy and typical symptoms have repeatedly proved poor at confirming GERD in these patients. Supporters argue that a twice-daily PPI course can be reasonable in patients with coexisting typical symptoms or after other causes have been investigated.

Alarm features

Alarm features shift the diagnostic approach from empirical treatment to early endoscopy. The American Society for Gastrointestinal Endoscopy recommends upper endoscopy for patients with GERD symptoms who have dysphagia, odynophagia, weight loss, gastrointestinal bleeding, persistent vomiting, or unexplained iron deficiency anemia. The American College of Gastroenterology similarly advises that patients with dysphagia or alarm symptoms be referred for endoscopy as soon as feasible. Older guidance linked these features to peptic strictures and esophagitis, but also observed that they cannot reliably predict complications, which limits their value as a screening tool. The lists of alarm symptoms are not fully consistent across sources: some earlier reviews also included chronic cough, hoarseness, choking, early satiety, and hematemesis, reflecting the uncertain boundary between atypical and complicated disease.

Phenotypes and classification

Erosive and non-erosive disease

Clinical definitions usually require heartburn or acid regurgitation at least weekly, whether or not endoscopy shows abnormalities. When reflux causes objective findings, such as oesophageal inflammation and ulceration, it is defined as erosive reflux disease. Upper endoscopy therefore separates the two main groups. The non-erosive group is large: between 50 and 75% of individuals with signs and symptoms suggestive of GERD display no visible erosions on EGD. Critics note that the label describes an absence of findings rather than a disease process, and some authors propose the wording "symptomatic reflux without visible endoscopic change" instead.

Standard grading systems also struggle with the milder end of the spectrum. The Los Angeles classification only distinguishes erosive from non-erosive disease, and does not take into account the minimal changes observed in patients with non-erosive disease. A modified scheme with a minimal-change grade is used in Japan. The Lyon Consensus treats severe erosive esophagitis (LA grades C and D), Barrett esophagus and peptic stricture as conclusive evidence of pathological reflux, while mild erosive esophagitis (LA grades A and B) is borderline or inconclusive evidence that should be confirmed by adjunctive supportive evidence. Advanced imaging has been explored to improve detection in non-erosive disease; studies have demonstrated that advanced endoscopy, including NBI magnification endoscopy and endocytoscopy, improved the diagnostic performance of white-light endoscopy alone, although these methods are not yet routine.

Symptom-based phenotypes defined by reflux monitoring

Once impedance-pH monitoring became available, endoscopy-negative heartburn was divided further. Patients with heartburn and a normal endoscopy can be classified into NERD (with abnormal acid exposure, positive or negative symptom reflux association), reflux hypersensitivity (normal acid exposure with positive symptom reflux association), and functional heartburn (normal acid exposure with negative symptom reflux association). The key distinction is therefore objective reflux burden combined with the statistical link between symptoms and reflux episodes.

The Rome criteria have shifted over time. Rome III kept reflux hypersensitivity within GERD, but the most recent Rome IV criteria proposed that HE should be renamed reflux hypersensitivity (RH) and should not be included within the GERD population. Rome IV attributes its symptoms mainly to visceral hypersensitivity rather than to abnormal acid exposure. Functional heartburn is defined by burning retrosternal discomfort or pain in patients who demonstrate a lack of symptom relief despite optimal antisecretory therapy in the absence of evidence of GERD, eosinophilic esophagitis, a major esophageal motor disorder.

Overlap and refractory symptoms

Phenotyping matters most in patients who do not respond to proton pump inhibitors. Reflux hypersensitivity is very common and together with functional heartburn accounts for more than 90% of the heartburn patients who failed treatment with proton pump inhibitor twice daily. Rome IV also allows for overlap: these two functional subgroups could overlap with true GERD, identified by the findings of positive reflux monitoring, EE, Barrett esophagus or peptic strictures in patients with persisting heartburn despite PPI therapy. In one small cohort of 119 patients with refractory symptoms, among 46 patients with proven GERD, 13 (28%) had isolated refractory GERD and 33 (72%) had an overlap of GERD and E-DGBIs. Functional dyspepsia and irritable bowel syndrome were common in the overlap group (functional dyspepsia (70.6%) and irritable bowel syndrome (33.6%) were highly prevalent, reported for the whole cohort). Such overlap is one reason that treatment for refractory symptoms may move toward neuromodulators and behavioural approaches rather than escalating acid suppression.

Unresolved boundaries

Several points remain contested. Some investigators argue that the concept that RH is not GERD is highly questionable, and others have argued that hypersensitive esophagus belongs to the GERD spectrum. The clinical value of the symptom association measures used to separate these groups has also been questioned. The clinical value of SAP and SI has been questioned. Rome IV's separation of functional from reflux-driven disease is also based on limited data, and the overlap studies have small samples. Whether the phenotypes represent distinct diseases or points on a continuum therefore remains open.

Complications: esophagitis, stricture and Barrett esophagus

Grading and course of erosive esophagitis

Erosive esophagitis is defined endoscopically by visible mucosal breaks in the distal esophagus. Its severity is most often graded with the Los Angeles (LA) classification, which runs from grade A to grade D according to the length and circumferential extent of the breaks. Grade A breaks are shorter than 5 mm. Grade B breaks are longer than 5 mm. Grade C breaks extend between two or more mucosal folds but involve less than 75% of the circumference. Grade D breaks involve at least 75% of the circumference. Grade A on its own is regarded as inconclusive evidence of GERD, so the grade carries most of its weight in prognosis and trial design.

Healing depends strongly on grade. In the ProGERD trial, esomeprazole 40 mg daily for eight weeks healed about 90% of patients with grade A or B disease but only about 77% of those with grade C or D. Across studies, once-daily proton pump inhibitor therapy heals roughly 60–70% of advanced (C/D) cases, which is why higher-grade disease is treated as an unmet need. Recurrence follows the same gradient. In a six-month maintenance study of patients with healed esophagitis on lansoprazole, relapse occurred in 23% of those with grade A/B disease and in 41% of those with grade C/D. Most patients relapse after acid suppression is stopped, so maintenance therapy is the usual approach, and some relapses are to a higher grade than at baseline. Bleeding is a recognised feature of severe disease, particularly grade C or D, and US administrative data recorded tens of thousands of hospital discharges with a diagnosis of esophagitis with bleeding over 2016–2019.

Peptic stricture

A peptic stricture is a fibrotic narrowing of the esophageal lumen that results from repeated episodes of acid-induced injury and healing. Pathologically, reflux-related fibrosis is generally submucosal rather than full-thickness, which is one reason that dilation can be effective. Estimates of its frequency vary, with one clinical source placing it in 1–5% of patients who develop esophagitis. Strictures due to acid reflux account for roughly 70–80% of benign esophageal strictures. They are usually shorter than 2 cm and lie within about 4 cm of the gastro-oesophageal junction.

Several mechanisms contribute. In one study, mean lower esophageal sphincter pressure was 4.9 mm Hg in patients with peptic strictures, 7.5 mm Hg in uncomplicated reflux disease and 20 mm Hg in controls, with no overlap between stricture patients and controls. Motility disorders were also more common in patients with strictures (about 64% versus 32%), and impaired clearance prolongs exposure of the mucosa to refluxed material. Large hiatal hernias and delayed gastric emptying add to the injury.

Patients typically present with progressive dysphagia, painful swallowing, and weight loss, and sometimes with food impaction. Barium esophagography and endoscopy with brushing and biopsy are used to separate a peptic stricture from malignant or other causes of dysphagia. Treatment rests on endoscopic dilation, usually performed in increments, with bougies and balloon dilators reported to be about equally effective. Symptoms improve with proton pump inhibitors and dilation, but around half of patients need repeated sessions, and each session carries a perforation risk of roughly 0.1–0.4%. Persistent heartburn after dilation is a strong predictor of early symptomatic recurrence, which suggests that inadequate acid control is a modifiable cause. Intralesional steroids have been used, but they carry risks of fungal superinfection, worsening esophagitis and perforation. Refractory strictures may require stenting or, in rare cases, esophagectomy.

Barrett esophagus

Barrett esophagus is intestinal metaplasia of the distal esophageal lining, in which squamous epithelium is replaced by columnar, goblet-cell-containing mucosa. It is typically asymptomatic and is the only identifiable precursor of esophageal adenocarcinoma. Progression is thought to follow a dysplasia–carcinoma sequence, from intestinal metaplasia to low-grade dysplasia, then high-grade dysplasia, then invasive adenocarcinoma. Established risk factors include chronic reflux symptoms, obesity, male sex, smoking and a family history. Segment length has also been associated with risk, with one Western estimate giving an odds ratio of about 1.11 for each additional centimetre. Dysplasia and early cancer often develop without warning, including in patients whose reflux symptoms are well controlled by acid suppression, which is the rationale for endoscopic surveillance.

The absolute annual risk of progression is contested. Surveillance schedules in earlier guidelines were built on an assumed risk of about 0.5% per year, derived from a 2000 meta-analysis that was later judged to overestimate risk because of publication bias. Earlier guidelines also used fixed intervals, such as three to five years without dysplasia, six to twelve months for low-grade dysplasia, and about three months for high-grade dysplasia. The 2025 American Gastroenterological Association guideline moved toward risk-based and individualized monitoring. It advises against routine surveillance for columnar-lined segments shorter than 1 cm without neoplasia, recommends high-definition white-light endoscopy combined with chromoendoscopy, and favours daily proton pump inhibitor therapy as the preferred preventive strategy. It made no formal recommendation for or against wide-area transepithelial sampling or biomarkers such as p53 and TissueCypher. The debate centres on missed lesions: pooled data cited in the guideline report a rate of about 17% of postendoscopy neoplasia in patients under surveillance, which has fuelled discussion about repeat examinations and sampling strategies.

Rarer complications

Beyond stricture and neoplasia, several less common complications have been described. Bleeding from ulcerated or friable mucosa can occur, mainly in severe disease, and deeper ulceration may lead to perforation, particularly during dilation. Secondary fungal infection of the stricture, most often by Candida species, has been documented in refractory cases. Food impaction and pulmonary aspiration are recognised complications of narrowed or dysmotile esophagi, and aspiration-related lung injury is the most significant of these, although its frequency is difficult to quantify.

Endoscopic and histological diagnosis

Upper endoscopy allows direct inspection of the esophageal mucosa, and it is the main means of documenting mucosal injury such as erosions, ulcers and the breaks that define erosive esophagitis. Its usefulness depends on the patient group. Upper endoscopy has high specificity but low sensitivity for GERD, and more than two-thirds of treatment-naïve patients with heartburn show no abnormality. A normal examination therefore does not exclude reflux disease, and a positive finding is informative mainly when it is present. For this reason, endoscopy is generally used in people with alarm features, such as dysphagia, weight loss, bleeding or anemia, where it can identify malignancy or other structural causes that need prompt investigation.

Acid-suppressive therapy is the most important confounder. In a study of patients with persistent dyspepsia, fewer endoscopic findings were seen in patients taking a proton pump inhibitor than in those taking an H2-receptor antagonist or receiving no therapy, and the authors concluded that partial symptom relief on a PPI may hide esophagitis. Conversely, performing endoscopy off PPI therapy increases the likelihood of an accurate diagnosis of erosive esophagitis, which is why many protocols favor a PPI-free interval before examination when clinically acceptable. The practical consequence is that long-term PPI use can continue without re-examination of the mucosa; a Japanese cohort found that long-term PPI administration without endoscopic monitoring of the esophageal mucosa is a common practice.

The Los Angeles (LA) classification is the most widely used system to describe the endoscopic appearance of reflux esophagitis and grade its severity. It grades lesions from A to D according to the length of mucosal breaks and whether they extend between the tops of adjacent folds. Its reproducibility, however, is more limited than its popularity suggests. In a post hoc analysis of a randomized trial, agreement between trial endoscopists and independent adjudicators was only fair (κ 0.27), whereas agreement between adjudicators and the final consensus diagnosis was good (κ 0.75–0.78). A study of 91 endoscopists using a modified LA system that adds a minimal-change grade reported a kappa of 0.094, indicating poor agreement. Experience matters: in a study of Spanish clinicians, inter-observer agreement was moderate among specialists (κ = 0.425) and acceptable among residents (κ = 0.297). Older analyses found that agreement was poor for grade 1 esophagitis but substantially better for erosive grades 2–4 (κ 0.68–0.79). Structured training modules have been shown to improve consistency in grading, and local protocols are often recommended to standardize reporting.

Biopsy is used less to confirm reflux than to exclude mimics and to identify complications. Histological features of reflux, such as elongated papillae and basal cell hyperplasia, are reactive changes within the squamous epithelium associated with inflammation and gastroesophageal reflux disease, but they are nonspecific. The most important mimic is eosinophilic esophagitis (EoE), which is defined by esophageal intraepithelial eosinophilia (≥15 eosinophils/high power field) together with other inflammatory features. Because the infiltrate is patchy, multiple biopsies obtained from three levels (proximal, middle, and distal) of the esophagus are recommended. A recent retrospective study of 511 adults found that about one in ten patients had eosinophilia confined to non-distal segments, leading to recommendations that biopsies from both the distal and middle esophagus be routinely included. PPIs complicate this picture because they have anti-inflammatory effects separate from acid suppression, so a PPI-responsive eosinophilic infiltrate can mislead both clinicians and pathologists.

In Barrett esophagus, biopsy is the only means of confirming intestinal metaplasia. Current recommendations advise biopsies from four quadrants at 2 cm intervals over the length of the segment, and the Seattle biopsy protocol includes targeted biopsies of all visible or suspected lesions plus four-quadrant random biopsies every 1–2 cm. A structured protocol of this kind is advised because focal lesions are easily missed. When metaplasia is suspected but not found histologically, repeat endoscopy at an interval of one to two years is suggested. The AGA guideline also recommends that acid suppressive therapy be optimized before BE surveillance to minimize interpretation challenges due to active esophagitis.

Several limitations apply across these methods. Endoscopic appearance is subjective, sampling is sparse, and acid suppression can both mask and mimic findings. Biopsy results are only as reliable as the sampling and the reading pathologist's criteria. The diagnostic value of endoscopy is therefore greatest when it is performed with a defined indication, an appropriate medication history, and a standardized reporting system.

Ambulatory reflux monitoring and the Lyon Consensus

Monitoring methods and metrics

Ambulatory reflux monitoring records how often and how long the distal esophagus is exposed to acid, and the main technologies differ in how they collect that data. Conventional 24-hour pH recording places a catheter through the nose, while wireless systems fix a single pH capsule to the esophageal wall. In the wireless approach, the sensor sends information to a receiver worn around the waist, and the device continually measures acid levels in the esophagus for up to 96 hours. pH-impedance monitoring adds impedance channels to the pH sensor, so it can register reflux events that are not necessarily acidic.

Acid exposure time (AET) is the anchor metric of interpretation, while the number of reflux episodes and mean nocturnal baseline impedance (MNBI) act as supporting measures. MNBI is derived from 10-minute average impedance values recorded during sleep at three one-hour intervals. Esophageal baseline impedance is a marker of esophageal mucosal integrity. A low MNBI therefore strengthens a reflux diagnosis when acid exposure alone is borderline.

The original Lyon Consensus (2018)

The original Lyon Consensus proposed a hierarchical approach to GERD diagnosis based on conventional and new impedance-pH metrics, namely acid exposure time, number of reflux episodes, post-reflux swallow-induced peristaltic wave index, and mean nocturnal baseline impedance. Within that scheme, an AET between 4% and 6% was considered inconclusive, and MNBI and the post-reflux swallow-induced peristaltic wave index could then confirm or refute GERD. The impedance thresholds were also revised: a cut-off of 2292 Ohms was first proposed and later changed in the second edition. The updated framework treats an MNBI below 1500 Ohms as strong evidence for GERD and a value above 2500 Ohms as a basis for refuting it.

Lyon Consensus 2.0 (2023)

The 2023 revision organizes its framework around the concept of actionable GERD. Testing strategy now depends on whether reflux has already been objectively documented, as the presence or absence of prior conclusive evidence for gastro-oesophageal reflux disease determines test strategy and methodology. Unproven cases are examined off antisecretory drugs, while proven cases with ongoing symptoms are examined on optimized therapy. The update also establishes Los Angeles grade B oesophagitis as conclusive GERD evidence, and criteria that have not performed well in the diagnosis of actionable GERD have been retired.

For prolonged wireless monitoring off therapy, an AET above 6.0% on two or more days supports GERD, whereas an AET below 4.0% on all days with a negative symptom association points against it. On therapy, an AET above 4% plus more than 80 reflux episodes is used to identify refractory reflux burden that may justify escalation of management.

Conflicting evidence on wireless testing

Comparisons between wireless and catheter-based methods do not agree. An earlier study of 48-hour wireless recording found that esophageal acid exposure was underestimated approximately by half compared with traditional recording, and its authors concluded that the two methods are not immediately interchangeable for use in clinical practice. A 2024 comparison in patients with chronic laryngeal symptoms reported the opposite pattern for yield: diagnostic yield for GER+ was significantly higher for wireless pH monitoring compared with 24-hour impedance monitoring: 50% (148/296) vs 27% (145/532). Uncertainty also remains about recording length, since there is a lack of data regarding the optimal duration of wireless studies, and day 1 results may be influenced by sedation.

Regional thresholds, access and limits

Normative thresholds may not transfer between populations. Patient age, body mass index and origin may affect MNBI values, which is why caution is advised before applying the published cut-offs. A 2025 single-centre study of 213 patients found that an MNBI cut-off of ≤3040 Ω best separated definite reflux from its absence, and 42% of patients had borderline or supportive findings, showing how many cases fall into grey zones. Practical limits also exist: a recent review lists global access to esophageal testing, disparities, dependence on specialized expertise, and regional variability in normative thresholds among the constraints on the consensus framework.

Differential diagnosis and overlapping conditions

Cardiac causes of chest pain

Reflux is the most common gastrointestinal cause of noncardiac chest pain, but that label applies only after a cardiac cause has been excluded, because the diagnosis cannot be assumed from the pain itself. The initial evaluation of chest pain is a focused history and cardiovascular examination aimed at acute coronary syndrome, aortic dissection and pulmonary embolism. Ischemia is usually excluded with an exercise stress test or coronary angiography, and a negative test or only mild single-vessel disease is generally adequate to rule out significant ischemia. The order matters because reflux-related pain can be hard to tell apart from a heart attack. Even after cardiac causes are removed, esophageal testing gives limited proof: 24-hour pH monitoring with symptom correlation can show an association between chest pain and reflux but does not prove causality.

Comparison with related upper gastrointestinal disorders

Functional dyspepsia is defined in Rome IV by one or more bothersome symptoms of postprandial fullness, early satiation, epigastric pain or epigastric burning, present for the last 3 months with onset at least 6 months earlier. In a study of patients meeting these criteria, endoscopic evidence of GERD did not exclude functional dyspepsia, and such patients were classed as having a GERD–functional dyspepsia overlap. By contrast, gastroduodenal ulcers and upper gastrointestinal tumors count as organic causes of dyspepsia and rule out functional dyspepsia. Peptic ulcer disease is therefore distinguished mainly by endoscopy.

Eosinophilic esophagitis requires a different workup. Upper endoscopy looking for linear furrows and/or mucosal biopsy is recommended to exclude it. Dysphagia can occur in it even without overt structural lesions, which is one reason the condition is hard to dismiss on symptoms alone.

Achalasia and other major esophageal motor disorders are also exclusion criteria. Rome IV names achalasia, jackhammer esophagus, distal esophageal spasm, absent contractility and esophagogastric junction outflow obstruction as the major motor disorders that must be absent. Motor findings are interpreted with caution: ineffective esophageal motility and fragmented peristalsis are not treated as exclusions, because these patterns also appear in asymptomatic people and may produce symptoms secondary to reflux, visceral hypersensitivity or hypervigilance.

The Rome criteria and the requirement to exclude GERD first

The Rome criteria are symptom-based classifications for disorders of gut–brain interaction. Rome IV, published in 2016, lists functional chest pain, functional heartburn, reflux hypersensitivity, globus and functional dysphagia as functional esophageal disorders. Each diagnosis is made by exclusion. Diagnosis of all functional esophageal disorders requires excluding GERD, eosinophilic esophagitis and a major esophageal motor disorder.

Rome IV also narrowed the definition of GERD. Its experts proposed that GERD should be diagnosed only in patients with abnormal esophageal acid exposure. Reflux hypersensitivity, formerly called hypersensitive esophagus, was moved out of GERD and into the functional group. Visceral hypersensitivity seems to be the predominant mechanism in these patients, who have physiologic acid exposure. This reclassification remains contested. If only patients with abnormal acid exposure are counted as having GERD, about 40% of the current NERD population is excluded from the disease. Rome IV also allows for overlap, and a small prospective study found similar clinical, psychological and functional profiles in conventional and GERD-overlapping functional heartburn, although its authors noted limited generalizability.

Respiratory and laryngeal conditions

Extraesophageal reflux presentations often do not fit the typical pattern. In one review, more than 75% of patients with extraesophageal symptoms had no typical heartburn or regurgitation and a negative upper endoscopy. Reflux that reaches the larynx and pharynx is termed laryngopharyngeal reflux, and it is found in about 20% of patients with chronic cough. Whether it is a variant of GERD or a separate entity is unresolved: although there may be some overlap, GERD and LPR may represent two distinct conditions with different management approaches.

The asthma relationship is similarly complex. Of people with asthma, 30% to 80% also have GERD, but cause and effect are difficult to separate. Determining whether LPR contributes to comorbid conditions or whether those conditions precipitate LPR remains challenging. In chronic cough, gastroesophageal reflux is considered the primary cause in non-smokers without asthma. Reflux can also appear as a respiratory condition through recurrent aspiration, which can present with asthma, a history of pneumonia and progressive pulmonary fibrosis. Laryngeal findings such as hoarseness can arise from chronic laryngeal irritation. Because cough, asthma and hoarseness have many other causes, these presentations are usually investigated jointly by gastroenterology, pulmonology and otolaryngology.

Lifestyle and dietary management

Lifestyle measures are usually the first step in managing gastroesophageal reflux disease, but the evidence behind most of them is weak to moderate. The American College of Gastroenterology (ACG) and the American Society for Gastrointestinal Endoscopy (ASGE) both recommend weight loss for people who are overweight or obese, smoking cessation, elevation of the head of the bed, and avoidance of meals within about two to three hours of bedtime. Most of these recommendations rest on low-certainty data. The ASGE panel rated the certainty of its overall evidence as very low, while noting that weight loss and smoking cessation have benefits for general health and cancer risk that extend beyond reflux.

Weight reduction

Weight loss has the most consistent support. Small trials in patients with obesity reported lower esophageal acid exposure after weight loss, and the ACG gave its strongest recommendation to weight reduction in overweight and obese patients, based on moderate-quality evidence. In a supervised weight-control trial of 332 patients, an average loss of about 13 kg was accompanied by a fall in reflux prevalence from 37% to 15% and a drop in symptom scores. A population-based cohort of nearly 30,000 people in Norway showed a dose-dependent relationship, with a fall in body mass index of 3.5 or more associated with a substantial reduction in symptoms. Because these data come largely from observational cohorts and uncontrolled or small interventional studies, causality and the size of the effect in non-obese patients remain uncertain.

Head-of-bed elevation and meal timing

Head-of-bed elevation is aimed mainly at nocturnal reflux, which prolongs acid exposure because swallowing and salivary buffering are reduced during sleep. A small 2012 study found that raising the head of the bed by a 20 cm block reduced supine acid exposure and acid clearance time, and sleep disturbance improved in about two-thirds of participants. Left lateral positioning has also been associated with fewer nocturnal symptoms in a systematic review and meta-analysis. The IBELGA trial, a randomized single-blind crossover study of 42 outpatients receiving proton pump inhibitors, found that six weeks of elevation significantly reduced reflux symptoms compared with a flat bed. Its authors nevertheless described the risk-benefit ratio as non-optimal and called for further studies before the measure is widely recommended. Earlier trials gave inconsistent results, and many predate the common use of proton pump inhibitors. Avoiding late meals is similarly widely advised, but systematic reviews have identified few high-quality trials supporting a specific cut-off time.

Dietary triggers

Commonly named triggers include fatty and fried foods, chocolate, coffee, alcohol, peppermint, carbonated drinks, citrus, tomatoes and spicy food. Physiological studies provide a plausible basis for some of these. Fat, chocolate (through cacao and methylxanthines), caffeine, alcohol and peppermint have all been shown to lower lower esophageal sphincter pressure in experimental settings, while coffee and some acidic foods may increase gastric acid secretion. Clinical evidence, however, is inconsistent. Observational studies have not confirmed a link between chocolate intake and symptoms, and ACG-based evidence grading rated the effect of fatty meals as equivocal while rating carbonated beverages as having moderate evidence. A widely cited evidence review of trials published between 1975 and 2004 found no published evidence that dietary interventions improved reflux measures. Responses also vary widely between individuals, so current guidance generally favors identifying personal triggers and avoiding them selectively rather than eliminating whole food groups. Practical substitutions, such as decaffeinated coffee, lean protein in place of fatty processed meat, or less acidic fruit, may improve adherence. Diets high in fiber have been associated with lower reflux risk in observational studies, but this has not been tested rigorously in trials.

Smoking, clothing and posture

Guidelines suggest avoiding tobacco, mainly on the basis of its effect on the lower esophageal sphincter and its broader health harms, but the direct evidence for symptom relief is limited. The same 1975–2004 review found no clear improvement in esophageal pH profiles or symptoms after tobacco or alcohol cessation. Advice to wear loose clothing and avoid tight waistbands, and to avoid bending or lying down soon after eating, is common in patient materials, yet trial evidence for these measures is sparse and mostly indirect.

Limits of the evidence and adherence

The evidence for lifestyle interventions is limited by small sample sizes, short follow-up, heterogeneous outcomes (symptom scores, acid exposure, or sphincter pressure), and the mixing of lifestyle advice with concurrent drug treatment. Many trials were conducted before proton pump inhibitors were widely used, and blinding is difficult for behavioral interventions, so placebo effects are hard to exclude. Long-term adherence is a further problem: sustained weight loss is difficult, head-of-bed elevation can be uncomfortable and disrupt sleep, and restrictive diets are hard to maintain. For these reasons, lifestyle measures are generally presented as low-cost adjuncts to pharmacological treatment rather than as stand-alone therapy for established disease.

Pharmacological therapy

Antacids and alginates

Antacids neutralize gastric acid directly and act quickly, but their effect is brief. The American College of Gastroenterology's guideline reserves them for on-demand relief and notes little evidence that one antacid formulation outperforms another. Alginates, usually combined with an antacid, form a viscous gel that floats on the gastric contents and may act as a physical barrier against reflux. Their use is usually considered an adjunct for occasional symptoms rather than a substitute for acid suppression in erosive disease.

Histamine H2 receptor antagonists

Histamine H2 receptor antagonists (H2RAs), such as famotidine, block the histamine signal that stimulates acid secretion by parietal cells, reducing acid output without fully stopping the proton pump. Their onset is relatively rapid, within about an hour, but their effect tends to weaken with continued daily use, so they are often taken twice daily on demand or before meals and at bedtime when nocturnal symptoms dominate. They are generally less potent than proton pump inhibitors (PPIs) and are considered an option for mild or intermittent symptoms, or as a step in a step-up approach.

Proton pump inhibitors

PPIs, including omeprazole, esomeprazole, lansoprazole, pantoprazole and rabeprazole, irreversibly inhibit the H⁺/K⁺ ATPase in the parietal cell membrane, the final step in acid secretion. Because the enzyme must be resynthesized, the full suppressive effect builds over several days of daily dosing. The standard approach is one dose daily, taken 30 to 60 minutes before the first meal, and the American Family Physician reference lists comparable daily doses of 20 mg for omeprazole, 40 mg for esomeprazole and pantoprazole, and 20 mg for rabeprazole. Among available drugs, PPIs remain the most effective agents for healing erosive esophagitis, and they are the standard reference for comparisons with newer drugs.

Potassium-competitive acid blockers

Potassium-competitive acid blockers (P-CABs) bind reversibly to the potassium-binding site of the proton pump and do not require acid activation of the pump. Vonoprazan, the most studied agent in this class, reaches its maximal plasma concentration within about two hours. In a phase 3 randomized trial comparing 8-week treatment of erosive esophagitis with lansoprazole, healing rates were 93% for vonoprazan 20 mg and 85% for lansoprazole 30 mg, with the advantage concentrated in Los Angeles grade C/D disease. Maintenance data up to 52 weeks showed recurrence rates below 10% with vonoprazan 10 or 20 mg. Longer use has been associated with hypergastrinemia, but no neoplastic change was identified in the reported long-term data. Most evidence comes from Asian populations, and the guideline positions P-CABs as an initial option for mild erosive disease, with on-demand use also studied for episodic symptoms.

Prokinetic agents

Prokinetics, such as metoclopramide and domperidone, aim to increase lower esophageal sphincter tone and accelerate gastric emptying. Their benefit in reflux is modest, and their use is limited by adverse effects, particularly neurological effects with metoclopramide. For this reason they are generally reserved for selected patients, for example those with delayed gastric emptying, rather than used as routine add-on therapy.

Step-up and step-down strategies

Two empiric strategies are described. In step-up therapy, an H2RA is tried first for about eight weeks and a PPI is added if heartburn and regurgitation persist. In step-down therapy, a PPI is started for about eight weeks and then reduced to the lowest effective dose or to a less potent drug once symptoms are controlled. The American Family Physician describes step-up and step-down as the preferred empiric approaches. Current guidance favors the empiric trial of a standard-dose PPI once daily, while step-down is most often applied in uncomplicated cases after an initial course of four to eight weeks. Step-down is not appropriate for patients with moderate to severe esophagitis (LA grade C or D) or Barrett esophagus, who typically need continuous acid suppression.

Long-term PPI safety and effectiveness

Observational and population-based cohort studies have linked long-term PPI use to pneumonia, major cardiovascular events, dementia, vitamin B12 deficiency, bone fractures, gastric cancer and kidney injury, but these associations are inconsistent and the evidence is considered weak, with rigorous causal evaluation lacking. Withdrawal can provoke rebound acid hypersecretion, which may lead patients to restart therapy and complicate deprescribing, and the duration of prior use predicts symptom recurrence after step-down. Randomized data suggest that on-demand PPI use can preserve symptom control in nonerosive disease: in one trial, 83% of patients given on-demand omeprazole were symptom-free at six months, compared with 56% on placebo. A meta-analysis of randomized trials likewise found on-demand PPI superior to daily dosing in maintaining remission, although the approach is not suitable for patients with erosive esophagitis of higher grade. The AGA recommends that patients who cannot reduce PPIs undergo ambulatory pH or pH-impedance monitoring before committing to lifelong therapy, so that GERD can be distinguished from a functional syndrome.

Surgical and endoscopic interventions

Laparoscopic fundoplication

Fundoplication reinforces the anti-reflux barrier by wrapping part of the gastric fundus around the distal esophagus. In the standard Nissen variant, the surgeon frees roughly 5 cm of distal esophagus, anchors the crura behind it, and forms a 360° posterior wrap secured with non-absorbable sutures (After the dissection of the crura of diaphragm, the distal esophagus was mobilized approximately 5 cm. The crura were sewn sutured behind the esophagus with 2–3 non-absorbable sutures. A 360° posterior fundus wrap was constructed with 2–3 non-absorbable sutures.). The laparoscopic route largely displaced the open operation before long-term results from controlled studies were available. A 15-year randomized trial comparing the two approaches concluded that the laparoscopic operation should remain the reference choice (The 15-year results obtained in the present study define laparoscopic Nissen fundoplication as the procedure of choice in the surgical management of GERD.). A systematic review limited to studies with at least ten years of follow-up found that LNF provides durable long-term improvement of GERD symptoms. Although postoperative gas-bloating and dysphagia are frequent, long-term patients' satisfaction is high.

Long-term results are not uniform across cohorts. In one series of 228 patients followed for at least 66 months, PPIs were used by 23% of patients at long-term follow-up, similar to most other reports. However, 35% of the original cohort was lost to follow-up. Other reports have cited much higher rates of medication use, which raised concerns about durability (62% of patients who have undergone laparoscopic Nissen fundoplication used PPIs at long-term follow-up).

Magnetic sphincter augmentation

Magnetic sphincter augmentation, most often performed with the LINX system, places a ring of magnetic beads around the lower esophageal sphincter to increase its closing force. MSA is designed to augment LES pressure while preserving the ability to belch and vomit, and because the stomach is not reshaped, the device avoids the anatomical changes of fundoplication. The device received FDA approval in 2012 following a multicenter trial. A meta-analysis of 39 studies covering more than 8,000 patients found that ten comparative studies set the device against fundoplication. In that comparison, the short-term rates of bloating (26.7% vs 53.4%) and dysphagia (33.9% vs 47.1%) were lower after augmentation, but neither difference reached statistical significance, and the authors called for longer comparative data (There was no statistically significant difference between MSA and LNF in gas/bloating (26.7 vs 53.4%, p = 0.06), postoperative dysphagia (33.9 vs 47.1%, p = 0.43) and proton pump inhibitor (PPI) elimination (81.4 vs 81.5%, p = 0.68). Magnetic sphincter augmentation appears to be an effective treatment for GERD with short-term outcomes comparable to the more technically challenging and time-consuming Nissen fundoplication. Long-term comparative outcome data past 1 year are needed). Selection criteria have also shifted over time: the initial trials that led to the approval of the LINX device excluded patients with a BMI > 35, and a feasibility study excluded patients with a hiatal hernia >3 cm.

Endoscopic and radiofrequency procedures

Transoral incisionless fundoplication (TIF) uses an endoluminal device to recreate a valve at the gastroesophageal junction. An earlier meta-analysis of 18 studies with 963 patients, published between 2007 and 2015, found that the pooled response to TIF exceeded that of PPIs or sham in randomized trials. However, the esophageal acid exposure time and acid reflux episodes after TIF were not significantly improved, and long-term results showed decreased efficacy with time. Patients often resume PPIs at reduced doses in the near future. A newer prospective multicenter cohort reported a more favorable picture, with clinical success in 94% of patients analyzed. Long-term data suggest that the percentage of patients who either stopped or halved their PPI therapy at 3-year follow-up seems nearly unchanged at 6 years (84%). Radiofrequency treatment of the sphincter (Stretta) is non-ablative, and it has been reported to help after failed Nissen fundoplication (Non-ablative radiofrequency treatment to the lower esophageal sphincter (Stretta) has been shown to be beneficial after failed Nissen fundoplication.). One US insurer's coverage policy, however, declined to recommend it as an anti-reflux procedure because of inconsistent data on the efficacy of the device.

Risks, complications and choosing surgery

Surgery carries a distinct adverse-effect profile. In a two-year cohort, dysphagia to solid and liquid occasionally appeared in 26.1% (N = 12) and 17.4% (N = 8) of patients, respectively. One series reported morbidity of 8.4% and a conversion rate of 2.79%. For magnetic augmentation, a meta-analysis reported a 0.1% rate of intra/perioperative complications. TIF studies report serious events such as perforation and bleeding in a minority of patients.

Surgery is generally considered after medical therapy fails. Current guidance treats laparoscopic fundoplication (LF) remains the recommended standard surgical approach for medically refractory GERD. Because nearly thirty-five percent of patients fail to achieve adequate symptom control with lifestyle changes and PPIs, the decision to operate often turns on whether symptoms persist after an adequate trial of drugs. Preoperative assessment typically includes endoscopy, objective studies to establish the diagnosis of GERD, including esophagogastroduodenoscopy, 24 h pH measurement study, and otorhinolaryngological examination. Symptom response after endoscopic procedures also correlates poorly with normalization of acid exposure, which complicates the assessment of outcomes (recent TIF studies confirm the poor correlation between post-TIF symptom control and pH normalization).

Special populations

Infants and children

Reflux in infancy is common and is often physiological. Pediatric guidelines describe gastro-oesophageal reflux as a normal process that occurs several times a day in healthy infants, with a peak around four months of age. Effortless regurgitation (spitting up) affects up to about 70% of healthy newborns and infants, and it resolves without treatment in roughly 95% of them by 12 to 14 months. For this reason, regurgitation is neither necessary nor sufficient for a diagnosis of GERD. The NASPGHAN–ESPGHAN joint guideline was revised partly because GERD had been diagnosed too readily in healthy infants with bothersome but harmless symptoms.

Pathological disease is suspected when the pattern departs from this picture. Repetitive vomiting in the first one to two weeks of life calls for exclusion of infection, anatomical anomaly and metabolic disorder. Onset of regurgitation after six months, or persistence beyond twelve months, should prompt consideration of other diagnoses. Bilious vomiting is not attributed to GERD, and recurrent vomiting with poor weight gain should not be labelled physiological reflux. The diagnosis rests mainly on history and examination, and investigations such as endoscopy and 24-hour pH testing are used selectively. Differential diagnoses include cow's milk protein allergy, eosinophilic esophagitis and congenital malformations. In formula-fed infants, thickened or anti-regurgitation formula reduces the frequency of overt regurgitation. In preterm infants, feeding intolerance, apnoea and feeding refusal are often attributed to reflux, but controlled data have not confirmed a causal link. Because a typical reflux syndrome cannot be diagnosed in children who cannot reliably report symptoms, complications such as esophagitis may be the only clue in these patients.

Pregnancy

Heartburn is frequent in pregnancy and may occur daily, becoming more frequent as gestation advances. Serious GERD-related complications are uncommon, and symptoms generally resolve after delivery. Management follows a stepwise approach. Lifestyle measures come first, including head-of-bed elevation, left lateral positioning and avoidance of trigger foods. If symptoms persist, pharmacological options are introduced in order: calcium-containing antacids or alginates, then sucralfate, then histamine H2 receptor antagonists such as famotidine, and finally proton pump inhibitors (PPIs) when breakthrough symptoms continue. Alarm features, including gastrointestinal bleeding, persistent vomiting, dysphagia, chest pain and involuntary weight loss, require further investigation rather than empirical treatment.

The main constraint is drug safety. Earlier practice often advised stopping PPIs around conception, but more recent large cohort studies and meta-analyses have not shown consistent associations between PPI use and adverse fetal outcomes. Some reviewers therefore regard PPIs as usable when clearly needed, while still preferring non-absorbable antacids and alginates as first-line agents because of their local action and minimal systemic absorption. Interventional comparative trials and pharmacokinetic studies in pregnant women remain limited.

Older adults

Older adults with GERD tend to report fewer typical symptoms but have more severe disease. Heartburn is less frequent in this group, and in one cited series acid regurgitation was reported in under a quarter of elderly patients. Dysphagia, chest pain, cough and hoarseness are more prominent. Retrosternal pain may be absent even in advanced esophagitis, and symptom intensity correlates poorly with the degree of mucosal inflammation. Several age-related factors contribute. Peristaltic clearance becomes less efficient, large hiatal hernias are more common and may be the most frequent benign cause of dysphagia in geriatric patients, and atrophic gastritis can raise gastric pH and blunt pain perception. Complications such as erosive esophagitis, stricture, Barrett esophagus and adenocarcinoma occur more often, and the presence of comorbidities and multiple medications complicates both diagnosis and treatment.

Chest pain in older patients may mimic angina, so cardiopulmonary causes must be evaluated before attributing symptoms to reflux. Older patients are also more likely to relapse after PPI discontinuation. Referral for upper endoscopy is generally advised for those with alarm features, those who do not respond to a PPI trial, or those with several risk factors for Barrett esophagus. Anaesthesia-related risks such as hypoxia, aspiration and arrhythmia are considered low overall but should be assessed individually.

Extraesophageal manifestations across groups

The extraesophageal spectrum differs among these groups. In older adults, atypical noncardiac chest pain, laryngitis, sinusitis, otitis media, dental erosion, chronic cough, asthma, aspiration pneumonia and sleep apnoea are reported, and these are often the presenting features. In infants, recurrent upper respiratory or ENT infections are treated as warning signs for possible GERD, although for most extraesophageal conditions in children a causal role has not been established. Extraesophageal presentations are described less systematically in pregnancy, where evaluation tends to focus on esophageal symptoms and alarm features. Across all three groups, attributing respiratory or laryngeal symptoms to reflux requires exclusion of other causes, as discussed in the differential diagnosis section.

Research history and evolution of diagnostic concepts

Before reflux could be measured directly, clinicians depended on provocation tests. The acid perfusion (Bernstein) test, introduced by Bernstein and Baker in 1958 as a clinical test for esophagitis, was later paired with esophageal pH monitoring as one of the two most common methods for gauging esophageal acid hypersensitivity. The acid perfusion (Bernstein) test and esophageal pH monitoring are the two most popular tests for identifying esophageal acid sensitivity in difficult cases of reflux disease. Bernstein LM, Baker LA: A clinical test for esophagitis. Gastroenterology 34:760–781, 1958

Continuous acid recording developed in stages. Spencer in 1969 published the first report on the use of prolonged intraesophageal pH monitoring to study GERD, but it was not until the mid-1970s that Johnson and DeMeester established the first normal values for this technique. Earlier electrodes were cumbersome. One indwelling setup allowed recordings of up to 12 hours, but this technique required that the patient keep their hands immersed in saline to serve as a reference. The practical step came in 1974, when Johnson and DeMeester developed a dependable external reference electrode. Their 24-hour protocol placed the sensor 5 cm above the upper border of the LOS and counted all events below pH 4. From the recordings they built a composite score, and the 95th percentile of that score, 14.72, became the normality limit used in many later studies. pH monitoring is not useful in diagnosing reflux esophagitis and, therefore, does not replace the endoscopic study.

The Montreal Consensus of 2006 was the first large attempt to standardise the concept. It was built through a modified Delphi process with 44 experts from 18 countries. Its authors framed GERD around troublesome symptoms and/or complications on account of reflux of stomach contents into the esophagus. The definition was deliberately independent of endoscopy, separated esophageal from extraesophageal syndromes, and recognised laryngitis, cough, asthma and dental erosions as possible GERD presentations. It also proposes a new definition for suspected and proven Barrett's esophagus. The consensus moved clinical attention toward symptoms, but it also had a side effect: most of the epidemiological studies used a standardized questionnaire that equated heartburn and regurgitation symptoms with GERD, and the diagnostic value of these typical symptoms was later questioned.

The Lyon Consensus of 2018 reintroduced objective evidence. It treated advanced grade erosive oesophagitis (LA grades C and D), long-segment Barrett's mucosa or peptic strictures on endoscopy or distal oesophageal acid exposure time (AET) >6% as conclusive proof of reflux disease, and held that clinical history, questionnaire data and response to antisecretory therapy are insufficient to make a conclusive diagnosis of GERD in isolation. Lyon Consensus 2.0 (2023) revised these rules. LA grade B oesophagitis was reclassified as conclusive evidence, and unproven versus proven GERD define diagnostic strategies and testing options. Unproven cases are studied off acid-suppressive drugs, while patients with conclusive GERD evidence (proven GERD) and persisting symptoms are evaluated using pH-impedance monitoring while on optimised antisecretory therapy. Criteria that performed poorly were removed, and wireless monitoring received its own thresholds, including an AET above 6% on at least two days as support for GERD.

The concept of actionable GERD marks the shift from classification toward individual management. It describes situations in which test results justify long-term acid suppression, escalation of medical therapy, or consideration of invasive procedures such as laparoscopic fundoplication, magnetic sphincter augmentation, endoscopic GERD therapies, or bariatric surgery. Lyon 2.0 states that personalisation of investigation and management to each patient's unique presentation will optimise GERD diagnosis and management. Its limits are practical as well as conceptual. The framework assumes access to advance diagnostic technologies for GERD that are unavailable, unaffordable, or unfeasible in the majority of global healthcare settings, interpretation of pH-impedance metrics is operator-dependent with significant inter-observer variability, and normative thresholds for reflux burden and baseline impedance may vary across geographic regions.

Public health, costs and quality of life

The economic weight of GERD is large, but published totals vary with the country, the method and the cost categories included. A trial registry entry describing the disease puts direct costs in the United States above $12 billion a year, with indirect costs possibly reaching $75 billion The economic burden is significant with direct costs exceeding $12 billion/year and indirect cost as high as $75 billion/year.. A systematic review of cost studies reports a UK figure of £760 million for healthcare and absenteeism combined, and a US figure of $24 billion In the United Kingdom, the estimated cost of healthcare and work absenteeism due to GERD is £760 million, whereas the cost is $24 billion in the United States. Outpatient care is the main channel. Since 2006 the condition has ranked as the most common gastrointestinal diagnosis at office visits, accounting for roughly 5% of ambulatory encounters Since 2006, GERD has been the most common gastrointestinal-related diagnosis in outpatient office visits, accounting for approximately 5% of all visits in the ambulatory setting.. In a community study from Iran, hospitalisation and physician visits were the largest direct costs, and the authors suggested that insurance arrangements could reduce them hospitalisation and physician visits were the main cost of disease that could be minimised by revision of the insurance business in Iran..

Medication is a major share of spending, and the dose matters. In a US claims analysis, patients on twice-daily proton pump inhibitor (PPI) therapy had mean GERD-related costs of $3749, compared with $2065 for once-daily users The mean total GERD-related costs in the post-index period for patients on twice-daily dosing were almost twice that of patients on once-daily dosing ($3749 versus $2065, respectively. A 2026 analysis reports that adults with a treated GERD record had unadjusted annual total healthcare expenditure of about $19,299, against about $7,825 for adults without one Unadjusted annual total healthcare expenditure averaged $19,298.94 (SE $464.91) among adults with a treated GERD record and $7,825.16 (SE $113.00) among adults without one. Across the studies cited in one review, medication, investigations and physician visits made up more than half, about one-third and about one-fifth of direct costs, respectively medication costs, investigations and physician visits accounted for over one-half, one-third and one-fifth of the direct costs, respectively.

Acid-suppressive drugs are also widely overused. A Canadian deprescribing guideline notes that chronic PPI use often lacks a documented indication, and that most GERD treatment is meant to be short-term Most common indications such as gastroesophageal reflux disease (GERD) require short-term treatment (ie, up to 4 to 8 weeks).. The guideline recommends reducing the dose, stopping, or switching to on-demand use for adults on continuous PPIs for more than 28 days whose symptoms have resolved, while excluding people with Barrett esophagus, severe esophagitis or a history of bleeding ulcers The recommendations do not apply to those who have or have had Barrett esophagus, severe esophagitis grade C or D, or documented history of bleeding gastrointestinal ulcers.. Estimates of inappropriate use are high: one review found that as many as 82% of PPI use fell outside evidence-based indications Studies have found upwards of 82% of PPIs are not being used following evidenced-based guidelines.. Deprescribing itself is hard to implement. A randomized trial in US veterans found that as-needed PPI use after withdrawal cut pill use but increased poorly controlled symptoms, with a relative risk of 1.71 Compared with continuous PPI use, the as-needed PPI regimen had a higher risk of poorly controlled symptoms (relative risk [RR] = 1.71; 95% CI, 1.31 to 2.21). Abrupt discontinuation in older patients with erosive esophagitis led to symptom return in about two-thirds of cases Symptoms returned in two-thirds of patients who abruptly stopped their PPI (67.9% vs. 22.4% for continuous use; RR = 3.02; 95% CI, 1.74 to 5.24).. Structured prompts in an internal medicine clinic raised the share of patients who stopped their PPI to 42%, compared with 20% when the prompt was not used The SmartPhrase interventions resulted in 42% of patients stopping their PPI compared to only 20% when the SmartPhrase was not used..

Symptoms that disturb sleep have effects beyond the night. In a survey of 11,685 people with GERD, most reported nighttime symptoms, and sleep difficulties were associated with additional provider visits, lower work productivity and more impairment in daily activities Of 11,685 survey respondents with GERD, 88.9 percent experienced nighttime symptoms, 68.3 percent sleep difficulties, 49.1 percent difficulty falling asleep and 58.3 percent difficulty staying asleep. These sleep difficulties were associated with a poorer HRQOL. Sleep difficulties were also associated with greater use of health-care resources (0.9 additional provider visits), loss of work productivity (5.5 percent decrease) and increased impairment of daily activities (10.9 percent increase).. In a European primary care study, absenteeism from GERD was highest in Germany at 3.2 hours a week and lowest in the UK at 0.4 hours, while presenteeism reached up to 6.7 hours a week in Norway Average absenteeism due to GERD was highest in Germany (3.2 hours/week) and lowest in the UK (0.4 hours/week), with an average of up to 6.7 additional hours/week lost due to presenteeism in Norway.. Quality-of-life losses are also measurable: among patients with moderate to severe GERD in Canada, mean utility scores were about 0.67 to 0.80 on a 0–1 scale depending on the instrument The mean scores on a scale from 0 (dead) to 1 (full health) obtained for the FT, SG, and HUI 3 were 0.67 (95% CI, 0.64 to 0.70), 0.76 (95% CI, 0.75 to 0.80), and 0.80 (95% CI, 0.77 to 0.82) respectively.. Psychological well-being is affected as well, since patients often describe fatigue and poorer mental health alongside their digestive symptoms Due to their esophageal and extra-esophageal symptoms, many patients with GERD regularly struggle to go about their everyday lives due to pain, fatigue, and feelings of poor physical and mental health.. Costs also rise when depressive symptoms coexist with GERD, with a combined odds ratio of 2.70 for top-decile spending in one analysis Both OR 2.70 0..

How much of this burden is reached in practice depends on health systems. Differences in insurance design, reimbursement, and the number of specialists shape whether patients can obtain pharmacological reassessment, endoscopy, ambulatory reflux monitoring or antireflux surgery, and these differences make international comparisons of cost and outcome difficult.

Unresolved questions and research directions

Long-term consequences of proton pump inhibitor use

The safety of long-term proton pump inhibitor (PPI) therapy is one of the most contested questions in this field. Many articles have linked long-term PPI therapy to unexpected adverse events, and these reports have alarmed patients and physicians alike. Much of that signal comes from observational designs. Most of these reports are observational, retrospective and prone to residual confounding.

The gastric cancer question illustrates the problem. Two nationwide analyses produced large effect estimates. One cohort of 63,397 people reported a hazard ratio of 2.44, and a much larger analysis of 797,067 people reported a standardized incidence ratio of 3.38, with risk rising alongside duration of use. Chronic PPI use is therefore associated with an increased risk of gastric cancer, but whether this association is causal, and whether it reflects the underlying indications for prescribing, has not been settled. Other findings are more specific. Fundic gland polyps develop more often during PPI therapy and regress after the drug is stopped. In the absence of Helicobacter pylori infection, a link between long-term use and progression of gastritis, atrophy or intestinal metaplasia has not been convincingly proven.

Associations with fractures, kidney disease, dementia and enteric infection have been reported as well. A recent systematic review of eight studies that met its inclusion criteria found the evidence still inconclusive for these outcomes. Results from randomized trials remain scarce, because harms that emerge over years are difficult to detect in short studies. Fear of these risks also has a clinical cost. Patients and providers, out of fear, may decrease or stop medications, which may lead to recurrent symptoms, esophagitis, or gastrointestinal hemorrhage. Open questions therefore include how dose, duration, age, co-medication and concurrent conditions modify risk, and whether deprescribing strategies can be made safe.

Biomarkers, genetics and the microbiome

Diagnosis still depends on pH-based measurement, endoscopy and biopsy. No validated blood or tissue biomarker can replace these tests for routine use. Candidate markers under study include pepsin and other components of refluxate, along with mucosal and salivary measures, but these remain research tools.

Genetic work has so far mostly consisted of association studies. Common variants associated with reflux-related traits and their shared architecture with other conditions such as obesity are areas of active investigation, but the contribution of any single locus to individual risk is modest. Work on the esophageal microbiome has compared communities across reflux disease, Barrett esophagus and healthy controls, with inconsistent results. It remains unclear whether microbial shifts cause mucosal injury, reflect inflammation, or change in response to acid suppression. Medication effects complicate this picture: long-term use is associated with decreased iron absorption and disruption in gut microbiota.

Machine learning for phenotypes and treatment response

Machine learning is being applied to define phenotypes and predict who will respond to treatment. A simulation study illustrates both the promise and the dependence on data quality. In a simulated randomized trial, recommending treatment on the basis of conventional analysis would have left 56.3% of patients failing to respond. A gradient-boosting model correctly predicted treatment response in 97.8% of patients, but when a single variable was omitted, accuracy dropped to 69.4%. The model's performance therefore depends on comprehensive phenotyping, which is rarely available in routine practice.

Applied GERD studies remain small and retrospective. A computer-based phenotype algorithm reached about 90% accuracy and the accuracy improved to 100% after one endoscopic rule was added, although these checks were made against expert review of the same cases. A model for laryngopharyngeal reflux drew on an internal dataset (n = 157) and external dataset (n = 53), and its accuracy was 82.98% internally and 84.91% externally. Such models depend on how response is defined. The laryngopharyngeal study, for instance, used a 50% fall in symptom scores as its cut-off, and the GERD authors note that phenotype-specific thresholds could be set without fixing response at 50%. Models also need external validation across health systems before they can guide individual treatment.

Refractory symptoms and overlap with functional disorders

Persistent symptoms despite PPI therapy are a central unresolved problem. The Rome IV framework recognised that functional heartburn and reflux hypersensitivity may overlap with GERD, a concept absent from earlier criteria. Estimates of how often this overlap explains refractory symptoms vary widely. Studies using 24-hour pH-impedance monitoring place the proportion of refractory patients with functional heartburn at roughly 21 to 40 percent, while one consensus paper suggests that functional heartburn, functional chest pain, or reflux hypersensitivity explain persistent symptoms in up to 75% of patients with GERD.

The mechanisms are also disputed. Functional disorders are thought to involve visceral hypersensitivity and hypervigilance. Acid itself appears not to provoke these symptoms: acid does not trigger functional heartburn symptoms, as evident from acid perfusion studies comparing functional heartburn to NERD patients. Diagnostic tools that could separate the two groups are imperfect. The metrics used to link reflux with symptoms do not always agree, and its clinical superiority over the SI has not been established unequivocally.

Trial evidence has been difficult to generate. A randomized trial of medical and surgical treatment enrolled patients with PPI-refractory heartburn, but only 78 patients completed the full assessment and were found to have GERD that was truly unresponsive to twice-daily PPIs. No demographic or clinical characteristics distinguished patients with reflux-related symptoms from those with functional heartburn. These problems explain why refractory symptoms, the boundary with functional disorders and the appropriate cut-offs for abnormal reflux remain active research problems.

References

1. Global Prevalence and Risk Factors of Gastro-oesophageal Reflux Disease (GORD): Systematic Review with Meta-analysisnature.com
2. Global prevalence and risk of gastroesophageal reflux disease symptoms in pregnancy: a systematic review and meta-analysislink.springer.com
3. (PDF) Global Prevalence and Risk Factors of Gastro-oesophageal Reflux Disease (GORD): Systematic Review with Meta-analysisresearchgate.net
4. Prevalence and Risk Factors of Gastroesophageal Reflux Disease Among University Students in Saudi Arabia: A Systematic Review and Meta-Analysis of Studies Up to 2025ncbi.nlm.nih.gov
5. Asian Patients Report Higher Reflux Symptom Burden than US Patients Despite Lower Objective Reflux Burden - PMCpmc.ncbi.nlm.nih.gov
6. Global prevalence and risk of gastroesophageal reflux disease symptoms in pregnancy: a systematic review and meta-analysis - PubMedpubmed.ncbi.nlm.nih.gov
7. (PDF) Epidemiology of Gastroesophageal Reflux Disease in Asia: A Systematic Reviewresearchgate.net
8. Gastroesophageal Reflux Disease in Asia: A historical perspective and present challenges - Goh - 2011 - Journal of Gastroenterology and Hepatology - Wiley Online Libraryonlinelibrary.wiley.com
9. Systematic Review on Epidemiology of Gastroesophageal Reflux Disease in Asia - Clinical Gastroenterology and Hepatologycghjournal.org
10. The prevalence of gastroesophageal reflux disease in Asian...researchgate.net
11. Trends in the burden of gastroesophageal reflux disease in China and Global from 1990 to 2021 and predictive analysis for 2040journals.plos.org
12. Risk factors for gastroesophageal reflux disease and analysis of genetic contributors - PubMedpubmed.ncbi.nlm.nih.gov
13. Prevalence and risk factors of gastroesophageal reflux disease among population of Saudi Arabiasmj.org.sa
14. The Lyon Consensus Criteria for GERD Diagnosis in a Greek Population: The Clinical Impact and Changes in GERD Diagnosis in a Real-World, Retrospective Studyncbi.nlm.nih.gov
15. Prevalence and risk factors of gastroesophageal reflux disease symptoms in Mazandaran, North of Iran: A Tabari cohort study - PMCpmc.ncbi.nlm.nih.gov
16. pmc.ncbi.nlm.nih.govpmc.ncbi.nlm.nih.gov
17. Gastroesophageal reflux disease in monozygotic and dizygotic twins - PubMedpubmed.ncbi.nlm.nih.gov
18. Chronic gastroesophageal reflux disease shares genetic background with esophageal adenocarcinoma and Barrett's esophagusacademic.oup.com
19. Transient Lower Esophageal Sphincter Relaxations and Reflux: Mechanistic Analysis Using Concurrent Fluoroscopy and High-Resolution Manometry - Gastroenterologygastrojournal.org
20. Transient Lower Esophageal Sphincter Relaxations Do Not Result From Passive Opening of the Cardia by Gastric Distention - Gastroenterologygastrojournal.org
21. Provocation of transient lower esophageal sphincter relaxations by gastric distension with air - ScienceDirectsciencedirect.com
22. The relevance of transient lower oesophageal sphincter relaxations in the pathophysiology and treatment of GORD - PMCpmc.ncbi.nlm.nih.gov
23. American Foregut Society Cooperative White Paper on Mechanisms of Pathologic Reflux and Antireflux Surgery - Ninh T. Nguyen, Barham Abu Dayyeh, Kenneth Chang, John Lipham, Reginald Bell, Francis Paul Buckley, Christy M. Dunst, Ravinder K. Mittal, Nirav Thosani, Brant K. Oelschlager, Marcelo W. Hinojosa, Vitor Brunaldi, Rena Yadlapati, Peter J. Kahrilas, 2025journals.sagepub.com
24. Pathophysiology of gastroesophageal reflux disease - Clínicas de Gastroenterología de Méxicoclinicasgastroenterologiademexico.com
25. Hiatal Hernia: Background, Pathophysiology, Etiologyemedicine.medscape.com
26. Esophageal Anatomy: The Antireflux Barrierlink.springer.com
27. Factors of Reflux Episodes With Post-reflux Swallow-induced Peristaltic Wave in Gastroesophageal Reflux Disease - PMCpmc.ncbi.nlm.nih.gov
28. Esophageal Clearance in Gastroesophageal Refluxlink.springer.com
29. Esophageal acid clearance - PubMed - NIHpubmed.ncbi.nlm.nih.gov
30. In vivo bicarbonate secretion by human esophagus - ScienceDirectsciencedirect.com
31. Saliva Production and Esophageal Motility Influence Esophageal Acid Clearance Related to Post-reflux Swallow-Induced Peristaltic Wave - PubMedpubmed.ncbi.nlm.nih.gov
32. Pathophysiology of Gastroesophageal Reflux Disease - Metabolic & Bariatric Care Timesbariatrictimes.com
33. The complexity of mucosal damage in gastroesophageal airway reflux disease: A molecular perspective - ScienceDirectsciencedirect.com
34. Pathophysiology of Gastroesophageal Reflux Diseasekarger.com
35. Pathologic assessment of lower esophageal sphincter damageimage-ppubs.uspto.gov
36. Bile salts disrupt human esophageal squamous epithelial barrier function by modulating tight junction proteinsjournals.physiology.org
37. Frontiersinfrontiersin.org
38. Inflammatory and Proliferative Pathway Activation in Human Esophageal Myofibroblasts Treated with Acidic Bile Saltsncbi.nlm.nih.gov
39. Inflammatory and Proliferative Pathway Activation in Human Esophageal Myofibroblasts Treated with Acidic Bile Salts - PMCpmc.ncbi.nlm.nih.gov
40. Progress on the Mechanism of Visceral Hypersensitivity in Nonerosive Reflux Diseasencbi.nlm.nih.gov
41. Distinct Microbiota Dysbiosis in Patients with Non-Erosive Reflux Disease and Esophageal Adenocarcinomadoi.org
42. The role of pepsin in acid injury to esophageal epithelium - ScienceDirectsciencedirect.com
43. Distinct Microbiota Dysbiosis in Patients with Non-Erosive Reflux Disease and Esophageal Adenocarcinoma - PMCpmc.ncbi.nlm.nih.gov
44. Treatment of non-erosive reflux disease and dynamics of the esophageal microbiome: a prospective multicenter studylink.springer.com
45. Multidimensional mechanisms and therapies underlying gastroesophageal reflux disease: focus on immunity, signaling pathways, and the microbiota-gut-brain axis - PMCpmc.ncbi.nlm.nih.gov
46. Frontiersfrontiersin.org
47. American Society for Gastrointestinal Endoscopy guideline on the diagnosis and management of GERD: summary and recommendations - Gastrointestinal Endoscopygiejournal.org
48. ACG Clinical Guideline: Guidelines for the Diagnosis and Management of Gastroesophageal Reflux Disease - PMCpmc.ncbi.nlm.nih.gov
49. Atypical Presentations of Gastroesophageal Reflux Diseaseaafp.org
50. Extraesophageal Symptoms and Diseases Attributed to GERD: Where is the Pendulum Swinging Now? - Clinical Gastroenterology and Hepatologycghjournal.org
51. Insights on Extraesophageal Gastroesophageal Reflux Disease - Gastroenterology & Hepatologygastroenterologyandhepatology.net
52. Assessment of Gastroesophageal Reflux Disease in Patients Exhibiting Otolaryngology Symptoms at a Tertiary Care Hospitalncbi.nlm.nih.gov
53. Presentation and Epidemiology of Gastroesophageal Reflux Disease - Gastroenterologygastrojournal.org
54. Approach to gastroesophageal reflux disease in primary care: Putting the Montreal definition into practice - PMCpmc.ncbi.nlm.nih.gov
55. Evaluation and management of gastroesophageal reflux disease: A brief look at the updated guidelinesccjm.org
56. Updated ACG Guidelines for Diagnosis and Treatment of GERDaafp.org
57. Atypical Symptoms of GERDmedcentral.com
58. Non Erosive Reflux Disease - an overviewsciencedirect.com
59. MINIMAL ENDOSCOPIC CHANGES IN NON-EROSIVE REFLUX DISEASE - PMCpmc.ncbi.nlm.nih.gov
60. The role of endoscopy in the management of gastroesophageal reflux diseasencbi.nlm.nih.gov
61. Advanced Endoscopy for Benign Esophageal Disease: A Review Focused on Non-Erosive Reflux Disease and Eosinophilic Esophagitisncbi.nlm.nih.gov
62. Comparison of oesophageal function tests between Chinese non-erosive reflux disease and reflux hypersensitivity patientsncbi.nlm.nih.gov
63. Recent insights on functional heartburn and reflux hypersensitivityncbi.nlm.nih.gov
64. Update on Functional Heartburn - PMC - NIHpmc.ncbi.nlm.nih.gov
65. Reflux Hypersensitivity: A New Functional Esophageal Disorderjnmjournal.org
66. Overlap of Esophageal Disorders of Gut-Brain Interactions... : Official journal of the American College of Gastroenterologyjournals.lww.com
67. Recent insights on functional heartburn and reflux hypersensitivityovid.com
68. (PDF) Critical appraisal of Rome IV criteria: Hypersensitive esophagus does belong to gastroesophageal reflux disease spectrumresearchgate.net
69. Overlap of esophageal disorders of gut-brain interactions (E-DGBIs) and GERD is highly prevalent in patients with refractory reflux symptomsresearchgate.net
70. When proton pump inhibitors fail in gastroesophageal reflux disease: a narrative review of overlapping esophageal disorders of gut-brain interaction - Syal - Annals of Esophagusaoe.amegroups.org
71. Comparison of Los Angeles Grades of Erosive Esophagitis Scored by Local Investigators vs Central Adjudicators in a Clinical Trial - ScienceDirectsciencedirect.com
72. Drug treatment strategies for erosive esophagitis in adults: a narrative review - PMCpmc.ncbi.nlm.nih.gov
73. Full article: Induction and maintenance of healing in erosive esophagitis in the United Statestandfonline.com
74. Reflux Esophagitis Phase III Study (Initial Treatment)clinicaltrials.gov
75. Efficacy of TAK-438 Compared to AG-1749 (Lansoprazole) in the Maintenance Treatment of Healed Erosive Esophagitisclinicaltrials.gov
76. Peptic Esophageal Stricturememorialhermann.org
77. Unique Case of a Refractory Esophageal Peptic Stricture in an Uncontrolled Diabetic - PMCpmc.ncbi.nlm.nih.gov
78. Dilation of Peptic Esophageal Stricturesebook.sts.org
79. Dilation of Peptic Esophageal Strictures - Operative Techniques in Cardiac and Thoracic Surgeryoptechtcs.com
80. PEPTIC STRICTURES OF THE ESOPHAGUS - ScienceDirectsciencedirect.com
81. Reflux esophagitis and peptic strictures : GI Motility onlinenature.com
82. AGA Issues New Guideline Urging Risk-Based Surveillance in Barrett’s Esophagus - The ASCO Postascopost.com
83. New Practice Guidance on Barrett’s Esophagus Surveillance Emphasizes Risk Stratificationmedscape.com
84. National Institute for Health and Care Excellence (NICE) guidance on monitoring and management of Barrett’s oesophagus and stage I oesophageal adenocarcinomancbi.nlm.nih.gov
85. Current status of surveillance for Barrett's esophagus in Japan and the Westncbi.nlm.nih.gov
86. AGA Clinical Practice Guideline on Surveillance of Barrett’s Esophagus - Gastroenterologygastrojournal.org
87. Experts urge risk-based monitoring as Barrett’s esophagus care moves beyond one-size-fits-all - American Gastroenterological Associationgastro.org
88. Screening and surveillance for Barrett’s esophagus: current issues and future directions - PMCpmc.ncbi.nlm.nih.gov
89. Role of endoscopy in gastroesophageal reflux diseasee-ce.org
90. Low yield of endoscopy in patients with persistent dyspepsia taking proton pump inhibitors - PubMedpubmed.ncbi.nlm.nih.gov
91. Upper Gastrointestinal Endoscopy off Proton Pump Inhibitor With Concurrent Telemetry Capsule pH Monitoring: Evidence Based and Cost Effective - Clinical Gastroenterology and Hepatologycghjournal.org
92. Endoscopic Examination and Long-term Use of Proton Pump Inhibitors fordovepress.com
93. (PDF) The Los Angeles Classification of Gastroesophageal Reflux Diseaseresearchgate.net
94. [Use of Los Angeles Classification in Erosive Esophagitis: analysis of inter-observer and intra-observer agreement] - PubMedpubmed.ncbi.nlm.nih.gov
95. Post-ablation lymphocytic esophagitis in Barrett esophagus with high grade dysplasia or intramucosal carcinomanature.com
96. Eosinophilic esophagitis, Barrett’s esophagus and esophageal neoplasms in the pediatric patient: a narrative review - Medina - Translational Gastroenterology and Hepatologytgh.amegroups.org
97. Interobserver agreement for the assessment of erosive reflux esophagitis: a post hoc analysis of clinical trial data - PubMedpubmed.ncbi.nlm.nih.gov
98. Interobserver agreement in endoscopic evaluation of reflux esophagitis using a modified Los Angeles classification incorporating grades N and M: A validation study in a cohort of Japanese endoscopistsacademic.oup.com
99. Training and Assessment of Clinician’s Utilization of the Los Angeles Classification for Reflux Esophagitis - Kayla Dadgar, Dennis Wang, Yuhong Yuan, Paul Sinclair, Prateek Sharma, David Armstrong, 2025journals.sagepub.com
100. (PDF) Los Angeles Classification of Esophagitis using Image Processing Techniquesresearchgate.net
101. New Eosinophilic Esophagitis Concepts Call for Change in Proton Pump Inhibitorgastrojournal.org
102. Yield of esophageal biopsy patterns for the diagnosis of eosinophilic esophagitis - Gastrointestinal Endoscopygiejournal.org
103. Seattle Protocol Is More Effective in Detection of Dysplasia Compared to Technology-Assisted Targeted Biopsies in Patients with Barrett’s Esophagusncbi.nlm.nih.gov
104. Wireless Esophageal pH Test (Bravo Test)hopkinsmedicine.org
105. Neuroregulators for the Treatment of Diseases Associated With Esophageal-brain-gut Axis Communication Abnormalities.cdn.clinicaltrials.gov
106. Mean nocturnal baseline impedance in gastro-esophageal reflux disease diagnosis: Should we strictly follow the Lyon 2 Consensus?doi.org
107. Prospective validation of reflux monitoring by impedance-pH in predicting PPI response in typical GERD - ScienceDirectsciencedirect.com
108. Applying Lyon consensus criteria in the work‐up of patients with extra‐oesophageal symptomsresearchgate.net
109. Mean nocturnal baseline impedance in gastro-esophageal reflux disease diagnosis: Should we strictly follow the Lyon 2 Consensus? - PMCpmc.ncbi.nlm.nih.gov
110. Lyon Consensus 2.0: what has changed for GERD diagnosis?: Expert Review of Gastroenterology & Hepatology: Vol 20, No 6tandfonline.com
111. Updates to the modern diagnosis of GERD: Lyon consensus 2.0 - PubMedpubmed.ncbi.nlm.nih.gov
112. (PDF) Updates to the modern diagnosis of GERD: Lyon consensus 2.0researchgate.net
113. Modern Diagnostic Strategies for Gastroesophageal Reflux Disease: Focus on Lyon Consensus 2.0 - PMCpmc.ncbi.nlm.nih.gov
114. Comparison of wireless 48-h (Bravo) versus traditional ambulatory 24-h esophageal pH monitoringresearchgate.net
115. Diagnostic Yield of Prolonged Wireless pH vs 24-hour pH-Impedance Monitoring for Evaluation of Chronic Laryngeal Symptoms - American College of Gastroenterologygi.org
116. 24 Versus 48-hour Bravo pH Monitoring : Journal of Clinical Gastroenterologyjournals.lww.com
117. Can the Mean Nocturnal Baseline Impedance/Acid Exposure Time Ratio Serve as a Novel Parameter for the Definitive Diagnosis of Pathological Reflux?ncbi.nlm.nih.gov
118. [Modern Diagnostic Strategies for Gastroesophageal Reflux Disease: Focus on Lyon Consensus 2.0] - PubMedpubmed.ncbi.nlm.nih.gov
119. Implications of the Updated Lyon Consensus 2.0 in Clinical Practiceresearchgate.net
120. Chest pain and gastroesophageal reflux disease - PubMedpubmed.ncbi.nlm.nih.gov
121. Diagnosis and Management of Noncardiac Chest Pain - Gastroenterology & Hepatologygastroenterologyandhepatology.net
122. The Evaluation of Effectiveness Between Empirical and Guided Therapy for Unexplained Non-Cardiac Chest Painclinicaltrials.gov
123. Noncardiac (GERD) Chest Pain: Location, Symptoms, Treatmentmy.clevelandclinic.org
124. Overlap of Gastroesophageal Reflux Disease and Functional Dyspepsia and Yield of Esophagogastroduodenoscopy in Patients Clinically Fulfilling the Rome IV Criteria for Functional Dyspepsiancbi.nlm.nih.gov
125. The Application of the Rome IV Criteria to Functional Esophagogastroduodenal Disorders in Asiajnmjournal.org
126. Diagnosis and Management of Functional Chest Pain in the Rome IV Erajnmjournal.org
127. Understanding the Rome IV: Esophageal Disordersekjm.org
128. Esophageal reflux hypersensitivity: Non-GERD or still GERD? - ScienceDirectsciencedirect.com
129. Narrative review of relationship between chronic cough and laryngopharyngeal refluxncbi.nlm.nih.gov
130. Laryngopharyngeal Reflux - StatPearls - NCBI Bookshelfncbi.nlm.nih.gov
131. Gastroesophageal reflux disease, laryngopharyngeal reflux, and vocal cord dysfunction/inducible laryngeal obstruction—overlapping conditions that affect asthma - ScienceDirectsciencedirect.com
132. Gastroesophageal Reflux Disease Differential Diagnosesemedicine.medscape.com
133. How Do I Handle the Patient With Noncardiac Chest Pain? - Clinical Gastroenterology and Hepatologycghjournal.org
134. American Society for Gastrointestinal Endoscopy guideline on the diagnosis and management of GERD: methodology and review of evidence - ScienceDirectsciencedirect.com
135. Lifestyle modifications in gastroesophageal reflux disease - Clínicas de Gastroenterología de Méxicoclinicasgastroenterologiademexico.com
136. Updates in Gastroesophageal Reflux Disease Management: From Proton Pump Inhibitors to Dietary and Lifestyle Modificationsmdpi.com
137. Systematic review: Clinical effectiveness of interventions for the treatment of nocturnal gastroesophageal reflux - Schuitenmaker - 2022 - Neurogastroenterology & Motility - Wiley Online Libraryonlinelibrary.wiley.com
138. Impact of head of bed elevation in symptoms of patients with gastroesophageal reflux disease: A randomized single-blind study (IBELGA)elsevier.es
139. Effect of bed head elevation during sleep in symptomatic patients of nocturnal gastroesophageal reflux - Khan - 2012 - Journal of Gastroenterology and Hepatology - Wiley Online Libraryonlinelibrary.wiley.com
140. jamanetwork.comjamanetwork.com
141. Heartburn, coffee, chocolate & spicescambridge.org
142. Dispelling Common Misconceptions: Unraveling the Truth About Common GERD Food Triggers - Canadian Digestive Health Foundationcdhf.ca
143. [Gastroesophageal Reflux Disease]pubmed.ncbi.nlm.nih.gov
144. Management of Gastroesophageal Reflux Diseaseaafp.org
145. Advances in Gastroesophageal Reflux Disease Management: Exploring the Role of Potassium-Competitive Acid Blockers and Novel Therapiesmdpi.com
146. Comparative Efficacy of Potassium-Competitive Acid Blockers (P-CABs) Versus Proton Pump Inhibitors (PPIs) in the Management of Erosive Esophagitis: A Systematic Reviewncbi.nlm.nih.gov
147. Vonoprazan Versus Lansoprazole for Healing and Maintenance of Healing of Erosive Esophagitis: A Randomized Trial - Gastroenterologygastrojournal.org
148. Randomised clinical trial: vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis - PubMedpubmed.ncbi.nlm.nih.gov
149. Potassium-Competitive Acid Blocker Suppression of Gastric Acid in Erosive Esophagitis: Is Stronger and Longer Better? - Gastroenterologygastrojournal.org
150. On-Demand Therapy with Proton Pump Inhibitors for Maintenance Treatment of Nonerosive Reflux Disease or Mild Erosive Esophagitis: A Systematic Review and Meta-Analysisncbi.nlm.nih.gov
151. The Risks and Benefits of Long-term Use of Proton Pump Inhibitors: Expert Review and Best Practice Advice From the American Gastroenterological Association - Gastroenterologygastrojournal.org
152. Long-Term Use of Proton-Pump Inhibitors: Unravelling the Safety Puzzlencbi.nlm.nih.gov
153. Holistic management of symptomatic reflux: rising to the challenge of proton pump inhibitor overusencbi.nlm.nih.gov
154. Cardiovascular Risk of Proton Pump Inhibitorsjournal.houstonmethodist.org
155. Long-Term Outcomes of Chronic Cough Reduction after Laparoscopic Nissen Fundoplication—A Single-Center Studyncbi.nlm.nih.gov
156. Fifteen-Year Outcome of Laparoscopic and Open Nissen Fundoplication: A Randomized Clinical Trial - The Annals of Thoracic Surgeryannalsthoracicsurgery.org
157. Laparoscopic Nissen Fundoplication Provides Strong Patient Satisfaction After 10 Yearsfacs.org
158. What is the long-term efficacy of laparoscopic Nissen fundoplication?nature.com
159. Comparative Outcomes of Laparoscopic Fundoplication and Magnetic Sphincter Augmentation for GERD: A Systematic Review and Meta-Analysismedrxiv.org
160. LINX® magnetic esophageal sphincter augmentation versus Nissen fundoplication for gastroesophageal reflux disease: a systematic review and meta-analysis - PubMedpubmed.ncbi.nlm.nih.gov
161. Criteria of patient selection for magnetic sphincter augmentationacademic.oup.com
162. SAGES LINX® Safety and Effectiveness Analysissages.org
163. Efficacy of transoral incisionless fundoplication (TIF) for the treatment of GERD: a systematic review with meta-analysis - PubMedpubmed.ncbi.nlm.nih.gov
164. Transoral incisionless fundoplication : Current Opinion in Gastroenterologyovid.com
165. The Benefits of Nonablative Radiofrequency Treatment of the Lower Esophageal Sphincter After Transoral Incisionless Fundoplication - PubMedpubmed.ncbi.nlm.nih.gov
166. Minimally Invasive Procedures for Gastric and Esophageal Diseases Page 1 of 31uhcprovider.com
167. The impact of laparoscopic Nissen fundoplication on the long-term quality of life in patients with gastroesophageal reflux disease - PubMedpubmed.ncbi.nlm.nih.gov
168. Long-term outcomes of quality of life after laparoscopic Nissen fundoplication - PubMedpubmed.ncbi.nlm.nih.gov
169. Patient Satisfaction after Laparoscopic Nissen Fundoplication—Long-Term Outcomes of Single-Center Studyncbi.nlm.nih.gov
170. Impact of Age on Long-Term Outcomes of Laparoscopic Nissen Fundoplication—A Single Center Studyncbi.nlm.nih.gov
171. Patient-reported outcomes of laparoscopic magnetic sphincter augmentation for gastro-oesophageal reflux diseasencbi.nlm.nih.gov
172. Magnetic sphincter augmentation in the management of gastro-esophageal reflux disease: a systematic review and meta-analysisncbi.nlm.nih.gov
173. Longest Study of Magnetic Sphincter Augmentation Shows Durable Efficacy of Linx® Reflux Management Systemjnjmedtech.com
174. Laparoscopic Magnetic Sphincter Augmentation (LINX)oregonclinic.com
175. Outcomes of transoral incisionless fundoplication (TIF 2.0): a prospective multicenter cohort study in academic and community gastroenterology and surgery practices (with video) - ScienceDirectsciencedirect.com
176. Transoral Incisionless Fundoplication (TIF) for Laryngopharyngeal Reflux (LPR) Patientsclinicaltrials.gov
177. Response of Laryngopharyngeal Symptoms to Transoral Incisionless Fundoplication in Patients with Refractory Proven Gastroesophageal Reflux - PubMedpubmed.ncbi.nlm.nih.gov
178. Diagnosis and Treatment of Gastroesophageal Reflux in Infants and Childrenaafp.org
179. [Infant gastroesophageal reflux disease: physiological or pathological ?] - PubMedpubmed.ncbi.nlm.nih.gov
180. Regurgitation in healthy and non healthy infants - PMC - NIHpmc.ncbi.nlm.nih.gov
181. Pediatric Gastroesophageal Reflux Clinical Practice ...espghan.org
182. Diagnosis and Management of Gastroesophageal Reflux Disease in Infants and Children: from Guidelines to Clinical Practicepghn.org
183. Pediatric Gastroesophageal Reflux Clinical Practice Guidelines:naspghan.org
184. Gastroesophageal Reflux Disease in the Pediatric Populationnaspghan.org
185. A Global, Evidence-based Consensus on the Definition of ...naspghan.org
186. Global prevalence and risk of gastroesophageal reflux disease symptoms in pregnancy: a systematic review and meta-analysis - PMCpmc.ncbi.nlm.nih.gov
187. Evidence-based treatment recommendations for gastroesophageal reflux disease during pregnancy: A reviewncbi.nlm.nih.gov
188. Gastroesophageal reflux disease and pregnancy: recommendations for safe treatment - PubMedpubmed.ncbi.nlm.nih.gov
189. Treatment of Gastroesophageal Reflux Disease During Pregnancy - PMCpmc.ncbi.nlm.nih.gov
190. GERD and the Elderly Patient: Clinical Considerations - Gastroenterology Advisorgastroenterologyadvisor.com
191. Frontiersfrontiersin.org
192. Review: Treatment of Gastroesophageal Reflux Disease in the Elderly - ScienceDirectsciencedirect.com
193. Gastroesophageal reflux disease: Important considerations for the older patientswjgnet.com
194. GERD and Aging: Adjusting Management Strategies Over Time - GERD Care Hubgerd.care
195. GERD in Older Adults: Here Are the Symptoms and Treatmentssiloamhospitals.com
196. Acid perfusion test and 24-hour esophageal pH monitoring with symptom indexlink.springer.com
197. Gastroesophageal reflux monitoring: pH and impedance : GI Motility onlinenature.com
198. Esophageal pH monitoringen.wikipedia.org
199. Oesophageal motility testing and 24-hour reflux studies - ScienceDirectsciencedirect.com
200. Esophageal Manometry and 24-Hour pH Monitoring to Evaluate Laparoscopic Lind Fundoplication in Gastroesophageal Reflux Disease - PMCpmc.ncbi.nlm.nih.gov
201. [PDF] The Montreal Definition and Classification of Gastroesophageal Reflux Disease: A Global Evidence-Based Consensussemanticscholar.org
202. Vakil N, van Zanten SV, Kahrilas P, et al. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol 2006;101(8):1900-1920.gastroscan.ru
203. (PDF) The Montreal definition and classification of Gastro-esophageal Reflux Disease (GERD)researchgate.net
204. Montreal, Rome, and Lyon Consensus: Will They Resolve the Conundrum of Gastroesophageal Reflux Disease - Gastroenterologygastrojournal.org
205. [PDF] Modern diagnosis of GERD: the Lyon Consensussemanticscholar.org
206. Clinical Application of Lyon Consensus 2.0 in Asia: An Overview - PMCpmc.ncbi.nlm.nih.gov
207. Implications of the Updated Lyon Consensus 2.0 in Clinical Practice - Mako Koseki, Emily S Seltzer, Kimberly Cavaliere, Yuying Luo, Daniela Jodorkovsky, 2025journals.sagepub.com
208. Revisiting Montreal: New Insights into Symptoms and Their... : Official journal of the American College of Gastroenterologyjournals.lww.com
209. Symptom Control Satisfaction With Proton Pump Inhibitor Regimenclinicaltrials.gov
210. Diagnosis and treatment of patients with gastroesophageal reflux diseaselink.springer.com
211. ClinicoEconomics and Outcomes Researchtandfonline.com
212. Economic burden of gastro-oesophageal reflux disease and dyspepsia: A community-based study - ScienceDirectsciencedirect.com
213. Comparison of health care resource utilization and costs among patients with GERD on once-daily or twice-daily proton pump inhibitor therapy - PMCpmc.ncbi.nlm.nih.gov
214. Frontiersfrontiersin.org
215. Deprescribing proton pump inhibitorscfp.ca
216. Deprescribing Proton Pump Inhibitors: Updated Clinical Guidelines - ScienceDirectsciencedirect.com
217. Deprescribing Chronic Use of Proton Pump Inhibitorsaafp.org
218. S1439 Oh My GERD: Reducing Proton Pump Inhibitor Overuse in an Internal Medicine Residency Clinicjournals.lww.com
219. GERD negatively impacts sleep quality, results in considerable economic burdeneurekalert.org
220. Impact of gastroesophageal reflux disease on work absenteeism, presenteeism and productivity in daily life: a European observational studyncbi.nlm.nih.gov
221. The impact of illness in patients with moderate to severe gastro-esophageal reflux diseasencbi.nlm.nih.gov
222. Impact of Gastroesophageal Reflux Disease (GERD) Symptoms on the Lifestyle and Academic Performance of Medical Students at King Faisal University - PMCpmc.ncbi.nlm.nih.gov
223. Evaluation of the National Randomized Proton Pump Inhibitor De-prescribing (RaPPID) Programcdn.clinicaltrials.gov
224. Problems Associated with Deprescribing of Proton Pump Inhibitorsncbi.nlm.nih.gov
225. Latest insights into the hot question of proton pump inhibitor safetysciencedirect.com
226. The Safety of Long-term Daily Usage of a Proton Pump Inhibitor: A Literature Reviewncbi.nlm.nih.gov
227. Safety of the long-term use of proton pump inhibitors - PMCpmc.ncbi.nlm.nih.gov
228. Long-Term Proton Pump Inhibitor Use and the Risk of Kidney Disease, Dementia, and Fractures: A Systematic Reviewncbi.nlm.nih.gov
229. Safety and Complications of Long-Term Proton Pump Inhibitor Therapy: Getting Closer to the Truth - Gastroenterologygastrojournal.org
230. A Systematic Review of the Adverse Effects of Long-Term Proton Pump Inhibitor Use on the Gastrointestinal System in the Adult Populationncbi.nlm.nih.gov
231. Machine learning detects hidden treatment response patterns only in the presence of comprehensive clinical phenotypingncbi.nlm.nih.gov
232. Computer-Based Intelligent Solutions for the Diagnosis of Gastroesophageal Reflux Disease Phenotypes and Chicago Classification 3.0 - PMCpmc.ncbi.nlm.nih.gov
233. Development of a Machine Learning Model to Predict Therapeutic Responses in Laryngopharyngeal Reflux Disease - PubMedpubmed.ncbi.nlm.nih.gov
234. Refractory Heartburn - The Esophagus - Wiley Online Libraryonlinelibrary.wiley.com
235. Refractory GERD: A Consensus Paper for Diagnosing and Managing Patients - Gastroenterology Advisorgastroenterologyadvisor.com
236. AGA Clinical Practice Update on Functional Heartburngiboardreview.com
237. Refractory Gastroesophageal Reflux Disease and Functional Heartburncpdcentre.co.za
238. Randomized Trial of Medical versus Surgical Treatment for Refractory Heartburnnejm.org
239. The Safety of Long-term Daily Usage of a Proton Pump Inhibitor: A Literature Review - PMCpmc.ncbi.nlm.nih.gov
240. Machine learning detects hidden treatment response patterns only in the presence of comprehensive clinical phenotypingjournals.plos.org
241. AGA Clinical Practice Update on Functional Heartburn: Expert Review - Gastroenterologygastrojournal.org
242. Treatment of Refractory Gastroesophageal Reflux Disease - Gastroenterology & Hepatologygastroenterologyandhepatology.net
243. Refractory Gastroesophageal Reflux Disease: Diagnosis and Managementjnmjournal.org